Novel S1P1 receptor agonists, crystalline salts, methods of preparation and related uses thereof

By developing (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopentadiene and[b]ind The crystalline salt of doly-3-yl)acetic acid, as an agonist of S1P1 receptor, solves the problem of major side effects of existing immunosuppressants in the treatment of immune diseases, and effectively inhibits lymphocyte migration and inflammatory responses, and prolongs grafts. Survive and reduce side effects.

CN118922405APending Publication Date: 2024-11-08ARENA PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380026322.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-02-17
Filing Date
2023-03-07
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing immunosuppressants have side effects in the treatment of autoimmune diseases, inflammatory diseases and transplant rejection, such as nephrotoxicity, neurotoxicity and gastrointestinal discomfort, and are difficult to effectively inhibit lymphocyte migration, resulting in limited therapeutic effects.

Method used

Development of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopentadiene-[b]indole -3-yl)acetic acid crystalline salt, as a selective agonist of S1P1 receptor, is used to inhibit lymphocyte migration and inflammatory response and reduce the side effects on bradycardia.

Benefits of technology

This compound effectively inhibits lymphocyte migration, reduces inflammation and immune response, prolongs graft survival, reduces side effects, and improves the effectiveness of treating inflammatory and immune diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922405A_ABST
    Figure CN118922405A_ABST
Patent Text Reader

Abstract

The present invention relates to crystalline salts of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl) benzyloxy)-1, 2, 3, 4-tetrahydrocyclopenta [b] indol-3-yl) acetic acid, and pharmaceutical compositions comprising them useful as modulators of the S1P1 receptor. The compound (R)-2-(9-chloro-7-(4-isopropoxy-3-(trifluoromethyl) benzyloxy)-2, 3-dihydro-1H-pyrrolo [1, 2-a] indol-1-yl) acetic acid is determined as an S1P1 receptor modulator, and can be used to treat S1P1 receptor related disorders, such as, for example, S1P1 receptor related disorders. In some embodiments, such as diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory disorders), cancer, and methods characterized by potential defects in vascular integrity or in conjunction with, for example, angiogenesis that may be pathological (e.g., acute and chronic inflammatory disorders). ) related conditions, such as may occur in inflammation, tumor development and atherosclerosis.
Need to check novelty before this filing date? Find Prior Art

Description

Field of the Invention

[0001] The present invention relates to a crystalline salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), and a pharmaceutical composition containing the same, which is particularly useful for treating S1P 1 Receptor-associated disorders, such as diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and disorders characterized by underlying defects in vascular integrity or associated with pathological angiogenesis (e.g., as may occur in inflammation, tumor development, and atherosclerosis). Background of the Invention

[0003] The present invention relates to compounds which are S1P1 receptor agonists having at least immunosuppressive, anti-inflammatory and / or hemostatic activity, for example, by modulating leukocyte trafficking, sequestering lymphocytes in secondary lymphoid tissues and / or enhancing vascular integrity.

[0004] The present application is focused, in part, on addressing the unmet need for immunosuppressants, e.g., orally available immunosuppressants, that have therapeutic efficacy for at least autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), transplant rejection, cancer, and / or conditions with underlying defects in vascular integrity or associated with, for example, angiogenesis that may be pathological (e.g., as may occur in inflammation, tumor development, and atherosclerosis), with fewer side effects, such as impairing the immune response to systemic infection.

[0005] Sphingosine-1-phosphate (S1P) receptors 1-5 form a family of G protein-coupled receptors with seven transmembrane domains. These receptors are called S1P1 to S1P5 (formerly known as endothelial differentiation gene (EDG) receptors-1, -5, -3, -6 and -8, respectively; Chun et al., Pharmacological Reviews, 54: 265-269, 2002), and are activated by the binding of sphingosine-1-phosphate, which is produced by sphingosine phosphorylation catalyzed by sphingosine kinase. S1P1, S1P4 and S1P5 receptors activate Gi but not Gq, while S1P2 and S1P3 receptors activate both Gi and Gq. S1P3 receptors, but not S1P1 receptors, respond to agonists with an increase in intracellular calcium.

[0006] S1P receptor agonists with agonist activity at the S1P1 receptor have been shown to rapidly and reversibly induce lymphopenia (also known as peripheral lymphopenia (PLL); Hale et al., Bioorg. Med. Chem. Lett., 14:3351-3355, 2004). This is achieved by clinically useful immunosuppression by sequestering T cells and B cells in secondary lymphoid tissues (lymph nodes and Peyer's patches), and thus away from sites of inflammation and organ transplantation (Rosen et al., Immunol. Rev., 195:160-177, 2003; Schwab et al., Nature Immunol., 8:1295-1301, 2007). This lymphocyte sequestration (e.g., in lymph nodes) is thought to be the result of simultaneous agonist-driven functional antagonism of S1P1 receptors on T cells (whereby the ability of S1P to mobilize T cells out of lymph nodes is reduced) and sustained agonism of S1P1 receptors on lymph node endothelium (thereby increasing the barrier function against lymphocyte migration) (Matloubian et al., Nature, 427:355-360, 2004; Baumruker et al., Expert Opin. Investig. Drugs, 16:283-289, 2007). It has been reported that agonism of the S1P1 receptor alone is sufficient to achieve lymphocyte sequestration (Sanna et al., J Biol Chem., 279:13839-13848, 2004), and that this occurs without compromising the immune response to systemic infection (Brinkmann et al., Transplantation, 72:764-769, 2001; Brinkmann et al., Transplant Proc., 33:530-531, 2001).

[0007] Agonism of endothelial cell S1P1 receptors has a broader role in promoting vascular integrity, supported by studies involving S1P1 receptors in mouse skin and lung capillary integrity (Sanna et al., Nat Chem Biol., 2:434-441, 2006). Vascular integrity can be disrupted by inflammatory processes (such as may result from sepsis, severe trauma and surgery), leading to acute lung injury or respiratory distress syndrome (Johan Groeneveld, Vascul. Pharmacol., 39:247-256, 2003).

[0008] An exemplary S1P receptor agonist with agonist activity at the S1P1 receptor is FTY720 (fingolimod), an immunosuppressant currently in clinical trials (Martini et al., Expert Opin. Investig. Drugs, 16:505-518, 2007). FTY720 acts as a prodrug that is phosphorylated in vivo; the phosphorylated derivative is an agonist of the S1P1, S1P3, S1P4, and S1P5 receptors (but not the S1P2 receptor) (Chiba, Pharmacology & Therapeutics, 108:308-319, 2005). FTY720 has been shown to rapidly and reversibly induce lymphopenia (also known as peripheral lymphocyte cytopenia (PLL)); Hale et al., Bioorg. Med. Chem. Lett., 14:3351-3355, 2004). This is achieved by virtue of clinically useful immunosuppression that sequesters T and B cells in secondary lymphoid tissues (lymph nodes and Peyer's patches) and thus away from sites of inflammation and organ transplants (Rosen et al., Immunol. Rev., 195:160-177, 2003; Schwab et al., Nature Immunol., 8:1295-1301, 2007).

[0009] In clinical trials, FTY720 caused adverse events (i.e., transient asymptomatic bradycardia) due to its agonistic effect on S1P3 receptors (Budde et al., J. Am. Soc. Nephrol., 13:1073-1083, 2002; Sanna et al., J. Biol. Chem., 279:13839-13848, 2004; Ogawa et al., BBRC, 361:621-628, 2007).

[0010] FTY720 has been reported to have therapeutic efficacy in at least the following: a rat model of autoimmune myocarditis and a mouse model of acute viral myocarditis (Kiyabayashi et al., J. Cardiovasc. Pharmacol., 35:410-416, 2000; Miyamoto et al., J. Am. Coll. Cardiol., 37:1713-1718, 2001); a mouse model of inflammatory bowel disease including colitis (Mizushima et al., Inflamm. Bowel Dis., 10:182-192, 2004; Deguchi et al., Oncology Reports, 16: 699-703, 2006; Fujii et al., Am. J. Physiol. Gastrointest. Liver Physiol., 291: G267-G274, 2006; Daniel et al., J. Immunol., 178: 2458-2468, 2007); Rat model of progressive mesangial proliferative glomerulonephritis (Martini et al., Am. J. Physiol. Renal Physiol., 292: F1761-F1770, 2007); mouse model of asthma, based on the study using S1P1 receptor agonist SEW2871, it was shown that it mainly mediated through S1P1 receptor (Idzko et al., J. Clin. Invest., 116: 2935-2944, 2006); mouse model of airway inflammation and induced bronchial hyperresponsiveness (Sawicka et al., J. Immunol., 171: 6206-6214, 2003); mouse model of atopic dermatitis (Kohno et al., Biol. Pharm. Bull., 27: 1392-1396, 2004); mouse model of ischemia-reperfusion injury (Kaudel et al., Transp. lant. Proc, 39:499-502, 2007); mouse model of systemic lupus erythematosus (SLE) (Okazaki et al., J. Rheumatol., 29:707-716, 2002; Herzinger et al., Am. J. Clin. Dermatol., 8:329-336, 2007); rat model of rheumatoid arthritis (Matsuura et al., Int. J. Immunopharmacol., 22:323-331, 2000; Matsuura et al., Inflamm. Res., 49:404-410, 2000); rat model of autoimmune uveitis (Kurose et al., Exp. Eye Res., 70:7-15, 2000); mouse model of type I diabetes (Fu et al., Transplantation, 73:1425-1430, 2002; Maki et al., Transplantation, 74:1684-1686, 2002; Yang et al., Clinical Immunology, 107:30-35, 2003; Maki et al., Transplantation, 79:1051-1055, 2005); mouse model of atherosclerosis (Nofer et al., Circulation, 115:501-508, 2007; Keul et al., Arterioscler. Thromb. Vasc. Biol., 27:607-613, 2007); rat model of brain inflammation after traumatic brain injury (TBI) (Zhang et al., J. Cell. Mol. Med., 11:307-314, 2007); mouse model of transplant coronary artery disease and graft-versus-host disease (GVHD) (Hwang et al., Circulation, 100:1322-1329, 1999; Taylor et al., Blood, 110:3480-3488, 2007). In vitro results suggest that FTY720 may have therapeutic efficacy against β-amyloid-related inflammatory diseases including Alzheimer's disease (Kaneider et al., FASEB J., 18:309-311, 2004). KRP-203 is an S1P receptor agonist with agonist activity at the S1P1 receptor and has been reported to have therapeutic efficacy in a rat model of autoimmune myocarditis (Ogawa et al., BBRC, 361:621-628, 2007). Using the S1P1 receptor agonist SEW2871, agonism of endothelial cell S1P1 receptors has been shown to prevent proinflammatory monocyte / endothelial cell interactions in the vascular endothelium of type I diabetes (Whetzel et al., Circ. Res., 99:731-739, 2006), and protect the vasculature from TNF-α-mediated monocyte / endothelial cell interactions (Bolick et al., Arterioscler. Thromb. Vasc. Biol., 25:976-981, 2005).

[0011] In addition, FTY720 has been reported to have therapeutic efficacy against experimental autoimmune encephalomyelitis (EAE) in rats and mice, a model of human multiple sclerosis (Brinkmann et al., J. Biol. Chem., 277:21453-21457, 2002; Fujino et al., J. Pharmacol. Exp. Ther., 305:70-77, 2003; Webb et al., J. Neuroimmunol., 153:108-121, 2004; Rausch et al., J. Magn. Reson. Imaging, 20:16-24, 2004; Kataoka et al., Cellular & Molecular Immunology, 2:439-448, 2005; Brinkmann et al., Pharmacology & Therapeutics, 115:84-105, 2007; Baumruker et al., Expert Opin. Investig. Drugs, 16: 283-289, 2007; Balatoni et al., Brain Research Bulletin, 74: 307-316, 2007). In addition, FTY720 has been found to have therapeutic efficacy in multiple sclerosis in clinical trials. In a Phase II clinical trial for relapsing-remitting multiple sclerosis, FTY720 was found to reduce the number of lesions detected by magnetic resonance imaging (MRI) and clinical disease activity in patients with multiple sclerosis (Kappos et al., N. Engl. J. Med., 355: 1124-1140, 2006; Martini et al., Expert Opin. Investig. Drugs, 16: 505-518, 2007; Zhang et al., Mini-Reviews in Medicinal Chemistry, 7: 845-850, 2007; Brinkmann, Pharmacology & Therapeutics, 115: 84-105, 2007). FTY720 is currently in Phase III studies for remitting-relapsing multiple sclerosis (Brinkmann, Pharmacology & Therapeutics, 115:84-105, 2007; Baumruker et al., Expert. Opin. Investig. Drugs, 16:283-289, 2007; Dev et al., Pharmacology and Therapeutics, 117:77-93, 2008).

[0012] Recently, FTY720 has been reported to have antiviral activity. Specific data have been shown in a lymphocytic choriomeningitis virus (LCMV) mouse model, in which mice were infected with the Armstrong or clone 13 strains of LCMV (Premenko-Lanier et al., Nature, 454, 894, 2008).

[0013] FTY720 has been reported to impair the migration of dendritic cells infected with Francisella tularensis to mediastinal lymph nodes, thereby reducing their bacterial colonization. Francisella tularensis is associated with tularemia, ulcerative gland infections, respiratory infections, and typhoid diseases (E. Bar-Haim et al., PLoS Pathogens, 4(11):e1000211.doi:10.1371 / journal.ppat.1000211, 2008).

[0014] It has also been recently reported that short-term high doses of FTY720 rapidly reduce ocular infiltrates in experimental autoimmune uveitis. When given in the early stages of ocular inflammation, FTY720 rapidly prevents retinal damage. It is reported not only to prevent infiltration of target organs, but also to reduce existing infiltration (Raveney et al., Arch. Ophthalmol. 126 (10), 1390, 2008).

[0015] Treatment with FTY720 has been reported to alleviate ovariectomy-induced osteoporosis in mice by reducing the number of mature osteoclasts attached to bone surfaces. The data provide evidence that S1P controls the migratory behavior of osteoclast precursors, dynamically regulating bone mineral homeostasis (Ishii et al., Nature, advance online publication, 8 February 2009, doi: 10.1038 / nature07713).

[0016] Agonism of the S1P1 receptor has been associated with enhanced survival of oligodendrocyte progenitor cells. Survival of oligodendrocyte progenitor cells is an essential component of the remyelination process. Remyelination of multiple sclerosis lesions is thought to promote recovery from clinical relapses. (Miron et al., Ann. Neurol., 63: 61-71, 2008; Coelho et al., J. Pharmacol. Exp. Ther., 323: 626-635, 2007; Dev et al., Pharmacology and Therapeutics, 117: 77-93, 2008). The S1P1 receptor has also been shown to play a role in platelet-derived growth factor (PDGF)-induced oligodendrocyte progenitor cell mitosis (Jung et al., Glia, 55: 1656-1667, 2007).

[0017] Agonism of the S1P1 receptor has also been reported to mediate the migration of neural stem cells to injured areas of the central nervous system (CNS), including in a rat model of spinal cord injury (Kimura et al., Stem Cells, 25: 115-124, 2007).

[0018] Agonism of the S1P1 receptor is associated with inhibition of keratinocyte proliferation (Sauer et al., J. Biol. Chem., 279: 38471-38479, 2004), consistent with reports that S1P inhibits keratinocyte proliferation (Kim et al., Cell Signal, 16: 89-95, 2004). Excessive proliferation of keratinocytes at the entrance of the hair follicle (which can subsequently become blocked), and the associated inflammation are important pathogenic factors of acne (Koreck et al., Dermatology, 206: 96-105, 2003; Webster, Cutis, 76: 4-7, 2005).

[0019] FTY720 has been reported to have therapeutic efficacy in inhibiting pathological angiogenesis (such as angiogenesis that may occur during tumor development). Inhibition of angiogenesis by FTY720 is believed to involve agonism of the S1P1 receptor (Oo et al., J. Biol. Chem., 282; 9082-9089, 2007; Schmid et al., J. Cell Biochem., 101: 259-270, 2007). FTY720 has been reported to have therapeutic efficacy in inhibiting primary and metastatic tumor growth in a mouse model of melanoma (LaMontagne et al., Cancer Res., 66: 221-231, 2006). FTY720 has been reported to have therapeutic efficacy in a mouse model of metastatic hepatocellular carcinoma (Lee et al., Clin. Cancer Res., 11: 84588466, 2005).

[0020] Oral administration of FTY720 to mice has been reported to effectively block VEGF-induced vascular permeability, an important process associated with angiogenesis, inflammation and pathological conditions such as sepsis, hypoxia and solid tumor growth (T Sanchez et al., J. Biol. Chem., 278(47), 47281-47290, 2003).

[0021] Cyclosporine A and FK506 (calcineurin inhibitors) are drugs used to prevent rejection of transplanted organs. Although they are effective in delaying or inhibiting transplant rejection, classical immunosuppressants such as cyclosporine A and FK506 are known to cause some undesirable side effects, including nephrotoxicity, neurotoxicity, beta cell toxicity and gastrointestinal discomfort. There is an unmet need for immunosuppressants without these side effects in organ transplantation, which are effective as monotherapy or in combination with classical immunosuppressants to inhibit, for example, the migration of alloantigen-reactive T cells to transplanted tissues, thereby prolonging graft survival.

[0022] FTY720 has been shown to have therapeutic efficacy in transplant rejection as both a monotherapy and in synergistic combination with classical immunosuppressants including cyclosporine A, FK506, and RAD (mTOR inhibitor). It has been shown that unlike the classical immunosuppressants cyclosporine A, FK506, and RAD, FTY720 has efficacy in prolonging graft survival without general immunosuppression, and this difference in drug action is thought to be related to the observed synergistic effect of the combination (Brinkmann et al., Transplant Proc., 33:530-531, 2001; Brinkmann et al., Transplantation, 72:764-769, 2001).

[0023] Agonism of the S1P1 receptor has been reported to have therapeutic efficacy in prolonging allograft survival in mouse and rat skin allograft models (Lima et al., Transplant Proc., 36:1015-1017, 2004; Yan et al., Bioorg. & Med. Chem. Lett., 16:3679-3683, 2006). FTY720 has been reported to have therapeutic efficacy in prolonging allograft survival in rat cardiac allograft models (Suzuki et al., Transpl. Immunol., 4:252-255, 1996). FTY720 has been reported to synergize with cyclosporine A to prolong rat skin allograft survival (Yanagawa et al., J. Immunol., 160:5493-5499, 1998), synergize with cyclosporine A and with FK506 to prolong rat heart allograft survival, and synergize with cyclosporine A to prolong canine kidney allograft survival and monkey kidney allograft survival (Chiba et al., Cell Mol. Biol., 3:11-19, 2006). KRP-203 is an S1P receptor agonist that has been reported to have therapeutic efficacy in prolonging allograft survival in a rat skin allograft model and in a rat heart allograft model both as monotherapy and in synergistic combination with cyclosporine A (Shimizu et al., Circulation, 111:222-229, 2005). KRP-203 has also been reported to have therapeutic efficacy in combination with mycophenolate mofetil (MMF; a prodrug whose active metabolite is mycophenolic acid, an inhibitor of purine biosynthesis) to prolong allograft survival in both rat kidney allograft models and rat cardiac allograft models (Suzuki et al., J. Heart Lung Transplant, 25:302-209, 2006; Fujishiro et al., J. Heart Lung Transplant, 25:825-833, 2006). An agonist of the S1P1 receptor, AUY954, has been reported to prolong rat cardiac allograft survival in combination with subtherapeutic doses of RAD001 (Certican / Everolimus, an mTOR inhibitor) (Pan et al., Chemistry & Biology, 13:1227-1234, 2006).In a rat small intestinal allograft model, FTY720 has been reported to synergize with cyclosporin A to prolong small intestinal allograft survival (Sakagawa et al., Transpl. Immunol., 13: 161-168, 2004). FTY720 has been reported to have therapeutic efficacy in a mouse islet transplant model (Fu et al., Transplantation, 73: 1425-1430, 2002; Liu et al., Microsurgery, 27: 300-304; 2007), and in studies using human islet cells, no deleterious effects on human islet function were demonstrated (Truong et al., American Journal of Transplantation, 7: 2031-2038, 2007).

[0024] FTY720 has been reported to reduce nociceptive behavior of neuropathic pain independent of prostaglandin synthesis in a model of selective injury of preserved nerves (O. Costu et al., Journal of Cellular and Molecular Medicine 12(3), 995-1004, 2008).

[0025] FTY720 has been reported to impair the initiation of contact hypersensitivity (CHS) in mice. Adoptive transfer of immunized lymph node cells from mice treated with FTY720 during the sensitization phase was virtually incapable of inducing CHS reactions in recipients (D. Nakashima et al., J. Investigative Dermatology (128(12), 2833-2841, 2008).

[0026] It has been reported that prophylactic oral administration of FTY720 (1 mg / kg, three times per week) completely prevents the development of experimental autoimmune myasthenia gravis (EAMG) in C57BL / 6 mice (T. Kohono et al., Biological & Pharmaceutical Bulletin, 28(4), 736-739, 2005).

[0027] In one embodiment, the present invention includes compounds that are agonists of the S1P1 receptor and are selective for the S1P3 receptor. The S1P3 receptor, rather than the S1P1 receptor, is directly associated with bradycardia (Sanna et al., J. Biol. Chem., 279: 13839-13848, 2004). S1P1 receptor agonists that are selective for at least the S1P3 receptor have advantages over current therapies by virtue of an enhanced therapeutic window, making higher doses better tolerated and thus improving efficacy as a treatment. The present invention includes compounds that are agonists of the S1P1 receptor and that exhibit no or substantially no activity for bradycardia.

[0028] S1P1 receptor agonists can be used to treat or prevent conditions for which suppression of the immune system or agonism of the S1P1 receptor is amenable, such as diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders, and conditions with underlying defects in vascular integrity or associated with angiogenesis, which may be pathological, for example.

[0029] In one embodiment, the present invention includes compounds that are agonists of the S1P1 receptor, have good overall physical properties and biological activity, and have an efficacy that is at least substantially greater than that of previous compounds active at the S1P1 receptor.

[0030] Citation of any reference in this application shall not be construed as an admission that such reference is prior art to the present application. SUMMARY OF THE INVENTION

[0032] It is difficult to predict with confidence a priori which salts of a particular compound will be solid, stable and easily separable. Chiral amine salts with optically active acids are no exception. Only through diligent experimentation can stable solid salts be discovered; however, once the salt is obtained, the ordinary technician has the ability to separate its diastereomers. In the process of preparing the salts of the present invention, many salt-forming agents commonly used in the pharmaceutical industry have been studied (see, for example, Berge et al., Journal of Pharmaceutical Sciences, 66: 1-19 (1977)).

[0033] One aspect of the present invention relates to certain amine-based crystalline salts of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) and pharmaceutically acceptable solvates and hydrates thereof.

[0034] One aspect of the present invention relates to certain crystalline amine-based salts of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1).

[0035] One aspect of the present invention relates to a crystalline salt selected from the following: (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid diethanolamine salt; (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid diethylamine salt and pharmaceutically acceptable solvates and hydrates thereof.

[0036] One aspect of the present invention relates to (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid diethanolamine salt.

[0037] One aspect of the present invention relates to (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid diethylamine salt.

[0038] One aspect of the present invention pertains to compositions comprising a crystalline salt, each as described herein.

[0039] One aspect of the present invention pertains to pharmaceutical compositions comprising a crystalline salt (each as described herein) and a pharmaceutically acceptable carrier.

[0040] One aspect of the present invention pertains to methods for treating an S1P1 receptor-associated disorder in an individual, comprising administering to the individual in need thereof a therapeutically effective amount of a crystalline salt or a pharmaceutical composition, each as described herein.

[0041] One aspect of the present invention pertains to methods for treating a disease or disorder mediated by lymphocytes in an individual, comprising administering to the individual in need thereof a therapeutically effective amount of a crystalline salt or a pharmaceutical composition, each as described herein.

[0042] One aspect of the present invention pertains to methods for treating an autoimmune disease or disorder in an individual, comprising administering to the individual in need thereof a therapeutically effective amount of a crystalline salt or a pharmaceutical composition, each as described herein.

[0043] One aspect of the present invention pertains to methods for treating an inflammatory disease or disorder in an individual, comprising administering to the individual in need thereof a therapeutically effective amount of a crystalline salt or a pharmaceutical composition, each as described herein.

[0044] One aspect of the present invention pertains to methods for treating a microbial infection or disease in an individual, comprising administering to the individual in need thereof a therapeutically effective amount of a crystalline salt or a pharmaceutical composition, each as described herein.

[0045] One aspect of the present invention pertains to methods for treating a viral infection or disease in an individual, comprising administering to the individual in need thereof a therapeutically effective amount of a crystalline salt or a pharmaceutical composition, each as described herein.

[0046] One aspect of the present invention pertains to methods for treating cancer in an individual, comprising administering to the individual in need thereof a therapeutically effective amount of a crystalline salt or a pharmaceutical composition, each as described herein.

[0047] One aspect of the present invention pertains to methods for treating a disorder in an individual, comprising administering to an individual in need thereof a therapeutically effective amount of a crystalline salt or a pharmaceutical composition, each as described herein, wherein the disorder is selected from the group consisting of psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, myocardial ischemia-reperfusion injury, hypertensive nephropathy, glomerulosclerosis, gastritis, polymyositis, thyroiditis, vitiligo, hepatitis, and biliary cirrhosis.

[0048] One aspect of the present invention relates to the use of a crystalline salt (each as described herein) in the preparation of a medicament for the treatment of an S1P1 receptor-associated disorder.

[0049] One aspect of the present invention pertains to the use of a crystalline salt (each as described herein) in the preparation of a medicament for the treatment of a disease or disorder mediated by lymphocytes.

[0050] One aspect of the present invention pertains to the use of a crystalline salt (each as described herein) in the preparation of a medicament for the treatment of an autoimmune disease or disorder.

[0051] One aspect of the present invention pertains to the use of a crystalline salt (each as described herein) in the preparation of a medicament for the treatment of an inflammatory disease or disorder.

[0052] One aspect of the present invention relates to the use of a crystalline salt (each as described herein) in the preparation of a medicament for treating a microbial infection or disease.

[0053] One aspect of the present invention relates to the use of a crystalline salt (each as described herein) in the preparation of a medicament for treating a viral infection or disease.

[0054] One aspect of the present invention relates to the use of a crystalline salt (each as described herein) in the preparation of a medicament for the treatment of cancer.

[0055] One aspect of the present invention relates to the use of a crystalline salt (each as described herein) in the preparation of a medicament for treating an S1P1 receptor-associated disorder selected from the group consisting of psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, myocardial ischemia-reperfusion injury, hypertensive nephropathy, glomerulosclerosis, gastritis, polymyositis, thyroiditis, vitiligo, hepatitis and biliary cirrhosis.

[0056] One aspect of the present invention pertains to a crystalline salt or a pharmaceutical composition (each as described herein) for use in a method of treatment of the human or animal body by therapy.

[0057] One aspect of the present invention pertains to a crystalline salt or a pharmaceutical composition (each as described herein) for use in a method of treating an S1P1 receptor-associated disorder.

[0058] One aspect of the present invention pertains to a crystalline salt or a pharmaceutical composition (each as described herein) for use in a method of treating a disease or disorder mediated by lymphocytes.

[0059] One aspect of the present invention pertains to a crystalline salt or a pharmaceutical composition (each as described herein) for use in a method of treating an autoimmune disease or disorder.

[0060] One aspect of the present invention pertains to a crystalline salt or a pharmaceutical composition (each as described herein) for use in a method of treating an inflammatory disease or disorder.

[0061] One aspect of the present invention pertains to a crystalline salt or a pharmaceutical composition (each as described herein) for use in a method of treating a microbial infection or disease.

[0062] One aspect of the present invention pertains to a crystalline salt or a pharmaceutical composition (each as described herein) for use in a method of treating a viral infection or disease.

[0063] One aspect of the present invention pertains to a crystalline salt, crystalline form, or pharmaceutical composition (each as described herein) for use in a method of treating cancer.

[0064] One aspect of the present invention pertains to a crystalline salt or a pharmaceutical composition (each as described herein) for use in a method of treating an S1P1 receptor-associated disorder selected from the group consisting of psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, myocardial ischemia-reperfusion injury, hypertensive nephropathy, glomerulosclerosis, gastritis, polymyositis, thyroiditis, vitiligo, hepatitis, and biliary cirrhosis.

[0065] One aspect of the present invention pertains to a process for preparing a composition comprising admixing a crystalline salt (each as described herein) and a pharmaceutically acceptable carrier.

[0066] One aspect of the present invention relates to a crystalline salt or a pharmaceutical composition, each as described herein, in the manufacture of a medicament for treating an S1P1 receptor-associated disorder.

[0067] One aspect of the present invention pertains to a crystalline salt or a pharmaceutical composition, each as described herein, for use in the manufacture of a medicament for treating a disease or disorder mediated by lymphocytes.

[0068] One aspect of the present invention pertains to a crystalline salt or a pharmaceutical composition, each as described herein, in the manufacture of a medicament for use in the treatment of an autoimmune disease or disorder.

[0069] One aspect of the present invention pertains to a crystalline salt or a pharmaceutical composition, each as described herein, in the manufacture of a medicament for use in the treatment of an inflammatory disease or disorder.

[0070] One aspect of the present invention pertains to a crystalline salt or a pharmaceutical composition, each as described herein, in the manufacture of a medicament for treating a microbial infection or disease.

[0071] One aspect of the present invention pertains to a crystalline salt or a pharmaceutical composition, each as described herein, in the manufacture of a medicament for treating a viral infection or disease.

[0072] One aspect of the present invention pertains to a crystalline salt or a pharmaceutical composition, each as described herein, in the manufacture of a medicament for the treatment of cancer.

[0073] One aspect of the invention pertains to a crystalline salt or pharmaceutical composition (each as described herein) for use in the preparation of a medicament for treating an S1P1 receptor-associated disorder selected from the group consisting of psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, myocardial ischemia-reperfusion injury, hypertensive nephropathy, glomerulosclerosis, gastritis, polymyositis, thyroiditis, vitiligo, hepatitis, and biliary cirrhosis.

[0074] One aspect of the present invention pertains to a crystalline salt or a pharmaceutical composition (each as described herein) for use in a method of treatment of the human or animal body by therapy.

[0075] One aspect of the present invention pertains to a crystalline salt or a pharmaceutical composition (each as described herein) for use in a method of treating an S1P1 receptor-associated disorder.

[0076] One aspect of the present invention pertains to a crystalline salt or a pharmaceutical composition (each as described herein) for use in a method of treating a disease or disorder mediated by lymphocytes.

[0077] One aspect of the present invention pertains to a crystalline salt or a pharmaceutical composition (each as described herein) for use in a method of treating an autoimmune disease or disorder.

[0078] One aspect of the present invention pertains to a crystalline salt or a pharmaceutical composition (each as described herein) for use in a method of treating an inflammatory disease or disorder.

[0079] One aspect of the present invention pertains to a crystalline salt or a pharmaceutical composition (each as described herein) for use in a method of treating a microbial infection or disease.

[0080] One aspect of the present invention pertains to a crystalline salt or a pharmaceutical composition (each as described herein) for use in a method of treating a viral infection or disease.

[0081] One aspect of the present invention pertains to a crystalline salt or a pharmaceutical composition (each as described herein) for use in a method of treating cancer.

[0082] One aspect of the present invention pertains to a crystalline salt or a pharmaceutical composition (each as described herein) for use in a method of treating an S1P1 receptor-associated disorder selected from the group consisting of psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, myocardial ischemia-reperfusion injury, hypertensive nephropathy, glomerulosclerosis, gastritis, polymyositis, thyroiditis, vitiligo, hepatitis, and biliary cirrhosis.

[0083] One aspect of the present invention pertains to a process for preparing a composition comprising admixing a crystalline salt (each as described herein) and a pharmaceutically acceptable carrier.

[0084] One aspect of the present invention pertains to crystalline salts and pharmaceutical compositions of the present invention, for use in a method of treatment of the human or animal body by therapy.

[0085] BRIEF DESCRIPTION OF THE DRAWINGS

[0086] Figure 1 : shows the powder X-ray diffraction (PXRD) pattern of a sample containing crystalline Compound 1 diethanolamine salt.

[0087] Figure 2 : shows a differential scanning calorimetry (DSC) thermogram of a sample containing crystalline Compound 1 diethanolamine salt.

[0088] Figure 3 : shows a thermogravimetric analysis (TGA) thermogram of a sample containing anhydrous crystalline Compound 1 diethanolamine salt.

[0089] Figure 4 : shows the powder X-ray diffraction (PXRD) pattern of a sample containing crystalline Compound 1 diethylamine salt.

[0090] Figure 5 : shows a differential scanning calorimetry (DSC) thermogram of a sample containing crystalline Compound 1 diethylamine salt.

[0091] Figure 6 : shows a thermogravimetric analysis (TGA) thermogram of a sample containing anhydrous crystalline Compound 1 diethylamine salt.

[0092] Details

[0093] It should be understood that certain features of the present invention are described in the context of separate embodiments for clarity, and may also be provided in combination in a single embodiment. Conversely, various features of the present invention are described in the context of a single embodiment for brevity, and may also be provided separately or in any suitable sub-combination.

[0094] definition

[0095] For clarity and consistency, the following definitions will be used throughout this patent document.

[0096] The term "agonist" refers to a moiety that interacts with a receptor such as an S1P1 receptor and activates the receptor and triggers a physiological or pharmacological response specific to the receptor. For example, when the moiety binds to the receptor, it activates an intracellular response or enhances the binding of GTP to the membrane.

[0097] The term "hydrate" as used herein refers to a compound of the present invention or a salt thereof, which further includes a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces.

[0098] When referring to treatment, the term "in need of treatment" and the term "in need" are used interchangeably and refer to the judgment made by a caregiver (e.g., in the case of humans, a physician, nurse, nurse practitioner, etc.; in the case of animals, including non-human mammals, a veterinarian) that an individual or animal requires or will benefit from treatment. This judgment is made based on a variety of factors within the professional knowledge of the caregiver, but it includes the knowledge that the individual or animal is or will become ill because of a disease, condition or disorder that is treatable by the compounds of the invention. Thus, the compounds of the invention can be used in a protective or preventive manner; or the compounds of the invention can be used to alleviate, inhibit or ameliorate a disease, condition or disorder.

[0099] The term "subject" refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, pigs, cows, sheep, horses, or primates, and most preferably humans.

[0100] The term "modulate" or "modulating" refers to an increase or decrease in the quantity, quality, response or effect of a specific activity, function or molecule.

[0101] The term "pharmaceutical composition" refers to a composition comprising at least one active ingredient; including but not limited to salts, solvates and hydrates of the compounds of the present invention; thus, the composition can be used to study specific, effective results in mammals (such as but not limited to humans). One of ordinary skill in the art will understand and appreciate the techniques suitable for determining whether an active ingredient has a desired effective result based on the needs of the technician.

[0102] The term "solvate" as used herein refers to a compound of the invention or a salt thereof, which further includes a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent intermolecular forces. Preferred solvents are volatile, non-toxic and / or acceptable for administration to humans in trace amounts.

[0103] The term "therapeutically effective amount" refers to the amount of an active compound or agent that will elicit the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical practitioner or other clinician or caregiver; or in an individual, it includes one or more of the following:

[0104] (1) preventing a disease; for example, preventing a disease, condition, or disorder in an individual who may be susceptible to the disease, condition, or disorder but who does not yet experience or display the pathology or symptoms of the disease,

[0105] (2) inhibiting a disease; for example, inhibiting a disease, condition, or disorder in an individual who is experiencing or exhibiting pathology or symptoms of the disease, condition, or disorder (i.e., preventing further development of the pathology and / or symptoms), and

[0106] (3) ameliorating a disease; e.g., ameliorating a disease, condition, or disorder in an individual who is experiencing or exhibiting the pathology or symptoms of the disease, condition, or disorder (i.e., reversing the pathology and / or symptoms).

[0107] The term "reacting" is used herein as known in the art and generally refers to bringing together chemical reagents in a manner to allow them to interact at a molecular level to achieve a chemical or physical transformation of at least one chemical reagent.

[0108] method

[0109] In particular, the present disclosure relates to methods useful for preparing crystalline forms of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for use in treating S1P1 receptor-related disorders.

[0110] One aspect of the present disclosure relates to a method for preparing a crystalline salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid comprising the steps of:

[0111] a) mixing (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid in an organic solvent to produce a suspension;

[0112] b) adding an amine to the suspension followed by water; and

[0113] c) isolating the crystalline salt.

[0114] One aspect of the present disclosure relates to a method for preparing a crystalline salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, wherein the organic solvent is selected from the group consisting of tetrahydrofuran (THF), 2-propanol, acetonitrile, ethyl acetate, ethanol, tert-butyl methyl ether (TBME), methyl isobutyl ketone (MIBK), water and dimethyl sulfoxide (DMSO), and combinations thereof.

[0115] One aspect of the present disclosure relates to a method of preparing a crystalline salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, wherein the organic solvent is acetonitrile.

[0116] One aspect of the present disclosure relates to a method for preparing a crystalline salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, wherein the amine is selected from the group consisting of diethylamine, dimethylethanolamine, ethanolamine, diethanolamine, morpholine, tromethamine, N-methyl-D-glucamine, diethylethanolamine and pyrrolidine.

[0117] One aspect of the present disclosure relates to a method of preparing a crystalline salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, wherein the amine is diethylamine.

[0118] One aspect of the present disclosure relates to a method of preparing a crystalline salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, wherein the amine is diethanolamine.

[0119] One aspect of the present disclosure relates to a method for preparing a crystalline salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, wherein the isolating step further comprises the following steps:

[0120] a) adding seed crystals of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, followed by stirring; and

[0121] b) cycling the temperature between 5°C and 40°C at a heating / cooling rate of 0.1°C / minute and holding at each temperature for 1 hour while stirring for 24 hours; and

[0122] c) The precipitated solid was collected by filtration.

[0123] One aspect of the present disclosure relates to a method of preparing a crystalline salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid prepared by the method described herein.

[0124] One aspect of the present disclosure relates to a method of preparing a composition comprising mixing a crystalline form of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid as described herein and a pharmaceutically acceptable carrier.

[0125] One aspect of the present disclosure relates to a method of preparing a composition, further comprising forming the composition into a pharmaceutical product, such as a tablet, pill, powder, lozenge, sachet, cachet, elixir, suspension, emulsion, solution, syrup, soft gelatin capsule, hard gelatin capsule, suppository, sterile injectable solution, or sterile packaged powder.

[0126] Salts of the present invention

[0127] The present invention particularly relates to solid, stable and easily isolable salts of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) and pharmaceutically acceptable solvates and hydrates thereof. The solid state properties of the crystalline forms of the salts of the present invention are summarized as follows.

[0128] One aspect of the present invention relates to a salt selected from the group consisting of: diethanolamine salt; diethylamine salt; and pharmaceutically acceptable solvates and hydrates thereof.

[0129] One aspect of the present invention relates to diethanolamine salts.

[0130] One aspect of the present invention relates to diethylamine salts.

[0131] One aspect of the present invention pertains to pharmaceutical compositions comprising a salt of the present invention.

[0132] One aspect of the present invention pertains to a process for preparing a pharmaceutical composition comprising admixing a salt of the present invention and a pharmaceutically acceptable carrier.

[0133] Crystalline salt

[0134] Polymorphism is the ability of a substance to exist in two or more crystalline phases that have different arrangements and / or conformations of molecules in the crystal lattice. Polymorphs display identical properties in the liquid or gaseous state, but they may behave differently in the solid state.

[0135] In addition to single-component polymorphs, drugs can also exist in the form of salts and other multi-component crystalline phases. For example, solvates and hydrates can contain an API host and solvent molecules or water molecules as guests, respectively. Similarly, when the guest compound is solid at room temperature, the form formed is generally referred to as a co-crystal. Salts, solvates, hydrates, and co-crystals can also show polymorphism. Crystalline phases that share the same API host but differ in their guest can be referred to as pseudo-polymorphs of each other.

[0136] Solvates contain solvent molecules crystallized in a defined crystal lattice. Solvates in which the solvent of crystallization is water are called hydrates. Since water is a component of the atmospheric air, hydrates of drugs can form fairly easily.

[0137] Recently, a polymorph screening of 245 compounds showed that about 90% of the compounds exhibited multiple solid forms. Overall, about half of the compounds were polymorphic, often with one to three forms. About one-third of the compounds formed hydrates, and about one-third formed solvates. Data from a cocrystal screening of 64 compounds showed that 60% formed cocrystals rather than hydrates or solvates. (GPStahly, Crystal Growth & Design (2007), 7 (6), 1007-1026.)

[0138] The present invention is particularly directed to crystalline salts of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) and hydrates and solvates thereof. The crystalline forms of the salts of the present invention can be identified by unique solid-state characteristics, such as differential scanning calorimetry (DSC), X-ray powder diffraction (PXRD), and other solid-state methods. Additional characterization of the water or solvent content of the crystalline salts of the present invention can be measured by any of the following methods, such as thermogravimetric analysis (TGA), DSC, etc. For DSC, it is known that the observed temperature will depend on the sample purity, the rate of temperature change, and the sample preparation technique and the specific instrument used. Therefore, the values ​​reported herein in connection with the DSC thermogram can vary by about ±6°C. The values ​​reported herein in connection with the DSC thermogram can also vary by about ±20 joules per gram. For PXRD, the relative intensities of the peaks can vary depending on the sample preparation technique, the sample installation procedure, and the specific instrument used. In addition, instrument changes and other factors typically affect 2θ values. Therefore, the peak attribution of the diffraction pattern can vary by about ± 0.2 ° 2θ. The relative intensity of the reported peaks can also vary. For TGA, the features reported herein can vary by about ± 5 ° C. The TGA features reported herein can also vary by about ± 2% weight change due to, for example, sample changes. Additional characterization of the hygroscopicity of the crystalline salt can be measured by, for example, dynamic moisture sorption (DMS). The DMS features reported herein can vary by about ± 5% relative humidity. The DMS features reported herein can also vary by about ± 5% weight change. The deliquescent relative humidity (DRH) measurement by a water activity meter is sensitive to sample quality and quantity. The DRH measurements reported herein can vary by about ± 5% RH.

[0139] Compound 1 diethanolamine salt.

[0140] One aspect of the present invention relates to (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid diethanolamine salt (Compound 1 diethanolamine salt). The physical properties of Compound 1 diethanolamine salt are summarized in Table 1 below.

[0141] Table 1

[0142]

[0143]

[0144] Compound 1 diethanolamine salt showed a weight loss (12.8%) as measured by TGA, corresponding to the loss of 0.8 equivalents of diethanolamine. The melting onset temperature by DSC was 123.5°C.

[0145] Certain X-ray powder diffraction peaks of the diethanolamine salt of Compound 1 are shown in Table 2 below.

[0146] Table 2

[0147]

[0148]

[0149] One aspect of the present disclosure relates to a diethanolamine salt having an X-ray powder diffraction pattern comprising peaks at 8.5°±0.2° and 11.6°±0.2°, expressed in 2θ. In some embodiments, the diethanolamine salt has an X-ray powder diffraction pattern comprising peaks at 8.5°±0.2°, 11.6°±0.2°, 11.8°±0.2°, and 12.1°±0.2°, expressed in 2θ. In some embodiments, the diethanolamine salt has an X-ray powder diffraction pattern comprising peaks at 8.5°±0.2°, 11.6°±0.2°, 11.8°±0.2°, 12.1°±0.2°, 13.1°±0.2°, 14.5°±0.2°, and 18.7°±0.2°, expressed in 2θ. In some embodiments, the diethanolamine salt has an X-ray powder diffraction pattern comprising peaks, expressed in 2θ, at 8.5°±0.2°, 11.6°±0.2°, 11.8°±0.2°, 12.1°±0.2°, 13.1°±0.2°, 14.5°±0.2°, 18.7°±0.2°, 20.1°±0.2°, 20.4°±0.2°, and 22.0°±0.2°. In some embodiments, the diethanolamine salt has an X-ray powder diffraction pattern comprising peaks expressed in 2θ at 8.5°±0.2°, 11.6°±0.2°, 11.8°±0.2°, 12.1°±0.2°, 13.1°±0.2°, 14.5°±0.2°, 18.7°±0.2°, 20.1°±0.2°, 20.4°±0.2°, 22.0°±0.2°, 22.2°±0.2°, 23.1°±0.2°, and 24.5°±0.2°. ... Figure 1 The X-ray powder diffraction pattern shown, where "substantially" means that the reported peaks may vary by about ±0.2° 2θ.

[0150] In some embodiments, the diethanolamine salt has a differential scanning calorimetry thermogram comprising an endothermic peak with an extrapolated onset temperature between about 120.5°C and about 130.4°C. In some embodiments, the diethanolamine salt has a differential scanning calorimetry thermogram comprising an endothermic peak with an extrapolated onset temperature between about 120.5°C and about 129.4°C. In some embodiments, the diethanolamine salt has a differential scanning calorimetry thermogram comprising an endothermic peak with an extrapolated onset temperature between about 121.5°C and about 129.4°C. In some embodiments, the diethanolamine salt has a differential scanning calorimetry thermogram comprising an endothermic peak with an extrapolated onset temperature between about 121.5°C and about 128.4°C. In some embodiments, the diethanolamine salt has a differential scanning calorimetry thermogram comprising an endothermic peak with an extrapolated onset temperature between about 122.5°C and about 128.4°C. In some embodiments, the diethanolamine salt has a differential scanning calorimetry thermogram comprising an endothermic peak with an extrapolated onset temperature at about 123.5° C. In some embodiments, the diethanolamine salt has substantially Figure 2 Differential Scanning Calorimetry thermogram shown, where "substantially" means that the reported DSC features can vary by about ±4°C and that the reported DSC features can vary by about ±20 joules per gram.

[0151] In some embodiments, the diethanolamine salt has a thermogravimetric analysis spectrum showing a weight loss of about 14.8% below about 130°C. In some embodiments, the diethanolamine salt has a thermogravimetric analysis spectrum showing a weight loss of about 13.8% below about 130°C. In some embodiments, the diethanolamine salt has a thermogravimetric analysis spectrum showing a weight loss of about 12.8% below about 130°C. In some embodiments, the diethanolamine salt has a thermogravimetric analysis spectrum showing a weight loss of about 12.8% below about 130°C. Figure 3 Thermogravimetric analysis patterns are shown, where "substantially" means that the reported TGA features can vary by about ±5°C and the reported TGA features can vary by about ±2% weight change.

[0152] One aspect of the present disclosure relates to diethanolamine salts having:

[0153] a) an X-ray powder diffraction pattern comprising peaks expressed in 2θ at 8.5°±0.2° and 11.6°±0.2°;

[0154] b) a differential scanning calorimetry thermogram comprising an endothermic peak with an extrapolated onset temperature between about 120.5°C and about 130.4°C; and / or

[0155] One aspect of the present disclosure relates to diethanolamine salts having:

[0156] a) an X-ray powder diffraction pattern comprising peaks, expressed in 2θ, at 8.5°±0.2°, 11.6°±0.2°, 11.8°±0.2° and 12.1°±0.2°;

[0157] b) a differential scanning calorimetry thermogram comprising an endothermic peak with an extrapolated onset temperature between about 120.5°C and about 129.4°C; and / or

[0158] One aspect of the present disclosure relates to diethanolamine salts having:

[0159] a) an X-ray powder diffraction pattern comprising peaks, expressed in 2θ, at 8.5°±0.2°, 11.6°±0.2°, 11.8°±0.2°, 12.1°±0.2°, 13.1°±0.2°, 14.5°±0.2° and 18.7°±0.2°;

[0160] b) a differential scanning calorimetry thermogram comprising an endothermic peak with an extrapolated onset temperature between about 121.5°C and about 129.4°C; and / or

[0161] One aspect of the present disclosure relates to diethanolamine salts having:

[0162] a) an X-ray powder diffraction pattern comprising peaks expressed in 2θ at 8.5°±0.2° and 11.6°±0.2°;

[0163] b) a differential scanning calorimetry thermogram comprising an endothermic peak with an extrapolated onset temperature between about 120.5°C and about 130.4°C; and / or

[0164] One aspect of the present disclosure relates to diethanolamine salts having:

[0165] a) an X-ray powder diffraction pattern comprising peaks, expressed in 2θ, at 8.5°±0.2°, 11.6°±0.2°, 11.8°±0.2°, 12.1°±0.2°, 13.1°±0.2°, 14.5°±0.2°, 18.7°±0.2°, 20.1°±0.2°, 20.4°±0.2°, and 22.0°±0.2°;

[0166] b) a differential scanning calorimetry thermogram comprising an endothermic peak with an extrapolated onset temperature between about 121.5°C and about 128.4°C; and / or

[0167] c) a thermogravimetric analysis spectrum showing a weight loss of about 14.8% below about 130°C; and / or

[0168] One aspect of the present disclosure relates to diethanolamine salts having:

[0169] a) an X-ray powder diffraction pattern comprising peaks, expressed in 2θ, at 8.5°±0.2°, 11.6°±0.2°, 11.8°±0.2°, 12.1°±0.2°, 13.1°±0.2°, 14.5°±0.2°, 18.7°±0.2°, 20.1°±0.2°, 20.4°±0.2°, 22.0°±0.2°, 22.2°±0.2°, 23.1°±0.2°, and 24.5°±0.2°;

[0170] b) a differential scanning calorimetry thermogram comprising an endothermic peak with an extrapolated onset temperature between about 122.5°C and about 128.4°C; and / or

[0171] c) a thermogravimetric analysis spectrum showing a weight loss of about 13.8% below about 130°C; and / or

[0172] One aspect of the present disclosure relates to diethanolamine salts having:

[0173] a) an X-ray powder diffraction pattern comprising peaks, expressed in 2θ, at 8.5°±0.2°, 11.6°±0.2°, 11.8°±0.2°, 12.1°±0.2°, 13.1°±0.2°, 14.5°±0.2°, 18.7°±0.2°, 20.1°±0.2°, 20.4°±0.2°, 22.0°±0.2°, 22.2°±0.2°, 23.1°±0.2°, and 24.5°±0.2°;

[0174] b) a differential scanning calorimetry thermogram comprising an endothermic peak with an extrapolated onset temperature at about 123.5°C; and / or

[0175] c) a thermogravimetric analysis spectrum showing a weight loss of about 12.8% below about 130°C; and / or

[0176] One aspect of the present disclosure relates to diethanolamine salts having:

[0177] a) Basically Figure 1 The X-ray powder diffraction pattern shown;

[0178] b) Basically Figure 2 The differential scanning calorimetry thermogram shown; and / or

[0179] c) Basically Figure 3 Thermogravimetric analysis spectrum shown.

[0180] Compound 1 diethylamine salt.

[0181] One aspect of the present invention relates to (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid diethylamine salt (Compound 1 diethylamine salt). The physical properties of Compound 1 diethylamine salt are summarized in Table 3 below.

[0182] Table 3

[0183]

[0184]

[0185] Compound 1 diethylamine salt showed a weight loss (2.9%) as measured by TGA, corresponding to the loss of 0.4 equivalents of acetonitrile or 1.3 equivalents of water. The melting onset temperature by DSC was 108°C.

[0186] Certain X-ray powder diffraction peaks of Compound 1 diethylamine salt are shown in Table 4 below.

[0187] Table 4

[0188]

[0189]

[0190] One aspect of the present disclosure relates to a diethylamine salt having an X-ray powder diffraction pattern comprising peaks at 7.9°±0.2° and 8.5°±0.2°, expressed in 2θ. In some embodiments, the diethylamine salt has an X-ray powder diffraction pattern comprising peaks at 7.9°±0.2°, 8.5°±0.2°, 12.8°±0.2°, and 15.6°±0.2°, expressed in 2θ.

[0191] In some embodiments, the diethylamine salt has an X-ray powder diffraction pattern comprising peaks, expressed in 2θ, at 7.9°±0.2°, 8.5°±0.2°, 12.8°±0.2°, 15.6°±0.2°, 15.9°±0.2°, and 17.0°±0.2°.

[0192] In some embodiments, the diethylamine salt has an X-ray powder diffraction pattern comprising peaks, expressed in 2θ, at 7.9°±0.2°, 8.5°±0.2°, 12.8°±0.2°, 15.6°±0.2°, 15.9°±0.2°, 17.0°±0.2°, 19.0°±0.2°, 19.3°±0.2°, and 19.8°±0.2°.

[0193] In some embodiments, the diethylamine salt has an X-ray powder diffraction pattern comprising peaks expressed in 2θ at 7.9°±0.2°, 8.5°±0.2°, 12.8°±0.2°, 15.6°±0.2°, 15.9°±0.2°, 17.0°±0.2°, 19.0°±0.2°, 19.3°±0.2°, 19.8°±0.2°, 20.3°±0.2°, 22.5°±0.2°, 23.1°±0.2°, and 26.8°±0.2°. ... Figure 4 The X-ray powder diffraction pattern shown, where "substantially" means that the reported peaks may vary by about ±0.2° 2θ.

[0194] In some embodiments, the diethylamine salt has a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature between about 104.6°C and about 119.4°C. In some embodiments, the diethylamine salt has a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature between about 104.6°C and about 118.4°C. In some embodiments, the diethylamine salt has a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature between about 105.6°C and about 118.4°C. In some embodiments, the diethylamine salt has a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature between about 105.6°C and about 117.4°C. In some embodiments, the diethylamine salt has a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature between about 106.6°C and about 116.4°C. In some embodiments, the diethylamine salt has a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature at about 107.6° C. In some embodiments, the diethylamine salt has substantially Figure 5 Differential Scanning Calorimetry thermogram shown, where "substantially" means that the reported DSC features can vary by about ±4°C and that the reported DSC features can vary by about ±20 joules per gram.

[0195] In some embodiments, the diethylamine salt has a thermogravimetric analysis spectrum showing a weight loss of about 4.9% below about 110°C. In some embodiments, the diethylamine salt has a thermogravimetric analysis spectrum showing a weight loss of about 3.9% below about 110°C. In some embodiments, the diethylamine salt has a thermogravimetric analysis spectrum showing a weight loss of about 2.9% below about 110°C. In some embodiments, the diethylamine salt has a thermogravimetric analysis spectrum showing a weight loss of about 2.9% below about 110°C. Figure 6 Thermogravimetric analysis patterns are shown, where "substantially" means that the reported TGA features can vary by about ±5°C and the reported TGA features can vary by about ±2% weight change.

[0196] One aspect of the present disclosure relates to diethylamine salts having:

[0197] a) an X-ray powder diffraction pattern comprising peaks expressed in 2θ at 7.9°±0.2° and 8.5°±0.2°;

[0198] b) a differential scanning calorimetry thermogram comprising an endothermic peak with an extrapolated onset temperature between about 104.6°C and about 119.4°C; and / or

[0199] One aspect of the present disclosure relates to diethylamine salts having:

[0200] a) an X-ray powder diffraction pattern comprising peaks, expressed in 2θ, at 7.9°±0.2°, 8.5°±0.2°, 12.8°±0.2° and 15.6°±0.2°;

[0201] b) a differential scanning calorimetry thermogram comprising an endothermic peak with an extrapolated onset temperature between about 104.6°C and about 118.4°C; and / or

[0202] One aspect of the present disclosure relates to diethylamine salts having:

[0203] a) an X-ray powder diffraction pattern comprising peaks, expressed in 2θ, at 7.9°±0.2°, 8.5°±0.2°, 12.8°±0.2°, 15.6°±0.2°, 15.9°±0.2° and 17.0°±0.2°;

[0204] b) a differential scanning calorimetry thermogram comprising an endothermic peak with an extrapolated onset temperature between about 105.6°C and about 118.4°C; and / or

[0205] One aspect of the present disclosure relates to diethylamine salts having:

[0206] a) an X-ray powder diffraction pattern comprising peaks, expressed in 2θ, at 7.9°±0.2°, 8.5°±0.2°, 12.8°±0.2°, 15.6°±0.2°, 15.9°±0.2°, 17.0°±0.2°, 19.0°±0.2°, 19.3°±0.2°, and 19.8°±0.2°;

[0207] b) a differential scanning calorimetry thermogram comprising an endothermic peak with an extrapolated onset temperature between about 105.6°C and about 117.4°C; and / or

[0208] c) a thermogravimetric analysis spectrum showing a weight loss of about 4.9% below about 110°C; and / or

[0209] One aspect of the present disclosure relates to diethylamine salts having:

[0210] a) an X-ray powder diffraction pattern comprising peaks, expressed in 2θ, at 7.9°±0.2°, 8.5°±0.2°, 12.8°±0.2°, 15.6°±0.2°, 15.9°±0.2°, 17.0°±0.2°, 19.0°±0.2°, 19.3°±0.2°, 19.8°±0.2°, 20.3°±0.2°, 22.5°±0.2°, 23.1°±0.2°, and 26.8°±0.2°;

[0211] b) a differential scanning calorimetry thermogram comprising an endothermic peak with an extrapolated onset temperature between about 106.6°C and about 116.4°C; and / or

[0212] c) a thermogravimetric analysis spectrum showing a weight loss of about 3.9% below about 110°C; and / or

[0213] One aspect of the present disclosure relates to diethylamine salts having:

[0214] a) an X-ray powder diffraction pattern comprising peaks, expressed in 2θ, at 7.9°±0.2°, 8.5°±0.2°, 12.8°±0.2°, 15.6°±0.2°, 15.9°±0.2°, 17.0°±0.2°, 19.0°±0.2°, 19.3°±0.2°, 19.8°±0.2°, 20.3°±0.2°, 22.5°±0.2°, 23.1°±0.2°, and 26.8°±0.2°;

[0215] b) a differential scanning calorimetry thermogram comprising an endothermic peak with an extrapolated onset temperature at about 107.6°C; and / or

[0216] c) a thermogravimetric analysis spectrum showing a weight loss of about 2.9% below about 110°C; and / or

[0217] One aspect of the present disclosure relates to diethylamine salts having:

[0218] a) Basically Figure 4 The X-ray powder diffraction pattern shown;

[0219] b) Basically Figure 5 The differential scanning calorimetry thermogram shown; and / or

[0220] c) Basically Figure 6 Thermogravimetric analysis spectrum shown.

[0221] One aspect of the present invention relates to a method for treating an S1P1 receptor-associated disorder in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a salt, crystalline form or pharmaceutical composition as described herein.

[0222] One aspect of the present invention pertains to methods for treating psoriasis in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a salt, crystalline form, or pharmaceutical composition as described herein.

[0223] One aspect of the present invention pertains to methods for treating rheumatoid arthritis in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a salt, crystalline form, or pharmaceutical composition as described herein.

[0224] One aspect of the present invention pertains to methods for treating Crohn's disease in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a salt, crystalline form or pharmaceutical composition as described herein.

[0225] One aspect of the present invention pertains to a method for treating transplant rejection in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a salt, crystalline form or pharmaceutical composition as described herein.

[0226] One aspect of the present invention pertains to methods for treating multiple sclerosis in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a salt, crystalline form or pharmaceutical composition as described herein.

[0227] One aspect of the present invention pertains to methods for treating systemic lupus erythematosus in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a salt, crystalline form, or pharmaceutical composition as described herein.

[0228] One aspect of the present invention pertains to methods for treating ulcerative colitis in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a salt, crystalline form, or pharmaceutical composition as described herein.

[0229] One aspect of the present invention pertains to methods for treating type I diabetes in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a salt, crystalline form, or pharmaceutical composition as described herein.

[0230] One aspect of the present invention pertains to methods for treating acne in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a salt, crystalline form, or pharmaceutical composition as described herein.

[0231] One aspect of the present invention pertains to methods for treating myocardial ischemia-reperfusion injury in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a salt, crystalline form, or pharmaceutical composition as described herein.

[0232] One aspect of the present invention pertains to methods for treating hypertensive nephropathy in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a salt, crystalline form, or pharmaceutical composition as described herein.

[0233] One aspect of the present invention pertains to methods for treating glomerulosclerosis in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a salt, crystalline form, or pharmaceutical composition as described herein.

[0234] One aspect of the present invention pertains to methods for treating gastritis in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a salt, crystalline form, or pharmaceutical composition as described herein.

[0235] One aspect of the present invention pertains to methods for treating polymyositis in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a salt, crystalline form, or pharmaceutical composition as described herein.

[0236] One aspect of the present invention pertains to methods for treating thyroiditis in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a salt, crystalline form, or pharmaceutical composition as described herein.

[0237] One aspect of the present invention pertains to methods for treating vitiligo in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a salt, crystalline form, or pharmaceutical composition as described herein.

[0238] One aspect of the present invention pertains to methods for treating hepatitis in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a salt, crystalline form or pharmaceutical composition as described herein.

[0239] One aspect of the present invention pertains to methods for treating biliary cirrhosis in an individual, comprising administering to said individual in need thereof a therapeutically effective amount of a salt, crystalline form, or pharmaceutical composition as described herein.

[0240] One aspect of the present invention pertains to the use of a salt or crystalline form as described herein in the preparation of a medicament for the treatment of psoriasis.

[0241] One aspect of the present invention pertains to the use of a salt or crystalline form as described herein in the preparation of a medicament for the treatment of rheumatoid arthritis.

[0242] One aspect of the present invention relates to the use of a salt or crystalline form as described herein in the preparation of a medicament for the treatment of Crohn's disease.

[0243] One aspect of the present invention relates to the use of a salt or crystalline form as described herein in the preparation of a medicament for the treatment of transplant rejection.

[0244] One aspect of the present invention relates to the use of a salt or crystalline form as described herein in the preparation of a medicament for the treatment of multiple sclerosis.

[0245] One aspect of the present invention pertains to the use of a salt or crystalline form as described herein in the preparation of a medicament for the treatment of systemic lupus erythematosus.

[0246] One aspect of the present invention pertains to the use of a salt or crystalline form as described herein in the preparation of a medicament for the treatment of ulcerative colitis.

[0247] One aspect of the present invention relates to the use of a salt or crystalline form as described herein in the preparation of a medicament for the treatment of type 1 diabetes.

[0248] One aspect of the present invention pertains to the use of a salt or crystalline form as described herein in the preparation of a medicament for the treatment of acne.

[0249] One aspect of the present invention relates to the use of a salt or crystalline form as described herein for the preparation of a medicament for the treatment of myocardial ischemia-reperfusion injury.

[0250] One aspect of the present invention relates to the use of a salt or crystalline form as described herein in the preparation of a medicament for the treatment of hypertensive nephropathy.

[0251] One aspect of the present invention relates to the use of a salt or crystalline form as described herein in the preparation of a medicament for the treatment of glomerulosclerosis.

[0252] One aspect of the present invention pertains to the use of a salt or crystalline form as described herein in the preparation of a medicament for the treatment of gastritis.

[0253] One aspect of the present invention relates to the use of a salt or crystalline form as described herein in the preparation of a medicament for the treatment of polymyositis.

[0254] One aspect of the present invention pertains to the use of a salt or crystalline form as described herein in the preparation of a medicament for the treatment of thyroiditis.

[0255] One aspect of the present invention relates to the use of a salt or crystalline form as described herein in the preparation of a medicament for the treatment of vitiligo.

[0256] One aspect of the present invention relates to the use of a salt or crystalline form as described herein in the preparation of a medicament for the treatment of hepatitis.

[0257] One aspect of the present invention relates to the use of a salt or crystalline form as described herein for the preparation of a medicament for the treatment of biliary cirrhosis.

[0258] One aspect of the present invention pertains to a salt, crystalline form or pharmaceutical composition as described herein, for use in a method of treatment of the human or animal body by therapy.

[0259] One aspect of the present invention pertains to a salt, a crystalline form or a pharmaceutical composition as described herein, for use in a method of treating psoriasis.

[0260] One aspect of the present invention pertains to a salt, a crystalline form or a pharmaceutical composition as described herein, for use in a method for the treatment of rheumatoid arthritis.

[0261] One aspect of the present invention pertains to a salt, crystalline form or pharmaceutical composition as described herein, for use in a method of treating Crohn's disease.

[0262] One aspect of the present invention pertains to a salt, a crystalline form or a pharmaceutical composition as described herein, for use in a method of treating transplant rejection.

[0263] One aspect of the present invention pertains to a salt, a crystalline form or a pharmaceutical composition as described herein, for use in a method of treating multiple sclerosis.

[0264] One aspect of the present invention pertains to a salt, a crystalline form or a pharmaceutical composition as described herein, for use in a method of treating systemic lupus erythematosus.

[0265] One aspect of the present invention pertains to a salt, a crystalline form or a pharmaceutical composition as described herein, for use in a method of treating ulcerative colitis.

[0266] One aspect of the present invention pertains to a salt, crystalline form or pharmaceutical composition as described herein, for use in a method for the treatment of type 1 diabetes.

[0267] One aspect of the present invention pertains to a salt, crystalline form or pharmaceutical composition as described herein, for use in a method of treating acne.

[0268] One aspect of the present invention pertains to a salt, crystalline form or pharmaceutical composition as described herein, for use in a method for treating myocardial ischemia-reperfusion injury.

[0269] One aspect of the present invention pertains to a salt, crystalline form or pharmaceutical composition as described herein, for use in a method of treating hypertensive nephropathy.

[0270] One aspect of the present invention pertains to a salt, a crystalline form or a pharmaceutical composition as described herein, for use in a method for the treatment of glomerulosclerosis.

[0271] One aspect of the present invention pertains to a salt, a crystalline form or a pharmaceutical composition as described herein, for use in a method for the treatment of gastritis.

[0272] One aspect of the present invention pertains to a salt, a crystalline form or a pharmaceutical composition as described herein, for use in a method of treating polymyositis.

[0273] One aspect of the present invention pertains to a salt, crystalline form or pharmaceutical composition as described herein, for use in a method of treating thyroiditis.

[0274] One aspect of the present invention pertains to a salt, crystalline form or pharmaceutical composition as described herein, for use in a method of treating vitiligo.

[0275] One aspect of the present invention pertains to a salt, crystalline form or pharmaceutical composition as described herein, for use in a method of treating hepatitis.

[0276] One aspect of the present invention pertains to a salt, a crystalline form or a pharmaceutical composition as described herein, for use in a method for the treatment of biliary cirrhosis.

[0277] Pharmaceutical composition

[0278] Other aspects of the present invention relate to pharmaceutical compositions comprising one or more salts according to any of the salt embodiments disclosed herein and one or more pharmaceutically acceptable carriers. Some embodiments relate to pharmaceutical compositions comprising a salt according to any of the salt embodiments disclosed herein and a pharmaceutically acceptable carrier. Some embodiments relate to pharmaceutical compositions comprising any subcombination of salts according to any of the salt embodiments disclosed herein.

[0279] Another aspect of the present invention relates to a method for preparing a pharmaceutical composition, comprising mixing one or more salts according to any of the salt embodiments disclosed herein and one or more pharmaceutically acceptable carriers. Some embodiments relate to a method for preparing a pharmaceutical composition, comprising mixing a salt according to any of the salt embodiments disclosed herein and a pharmaceutically acceptable carrier. Some embodiments relate to a method for preparing a pharmaceutical composition, comprising mixing any subcombination of salts according to any of the salt embodiments disclosed herein and a pharmaceutically acceptable carrier.

[0280] The formulations may be prepared by any suitable method, generally by uniformly mixing the active salt(s) with a liquid or finely divided solid carrier, or both, in the required proportions and then, if necessary, shaping the resulting mixture into the desired form.

[0281] Conventional excipients, such as adhesives, fillers, acceptable wetting agents, tableting lubricants and disintegrants can be used in tablets and capsules for oral administration. Liquid preparations for oral administration can be in the form of solutions, emulsions, water or oil suspensions and syrups. Alternatively, oral preparations can be in the form of dry powders, which can be reconstituted with water or another suitable liquid vehicle before use. Other additives such as suspending agents or emulsifiers, non-aqueous vehicles (including edible oils), preservatives and flavorings and coloring agents can be added to the liquid preparation. Parenteral dosage forms can be prepared by dissolving the salt of the present invention in a suitable liquid vehicle and filtering and sterilizing the solution before filling and sealing a suitable vial or ampoule. These are just a few examples of many well-known appropriate methods for preparing dosage forms in the art.

[0282] The salt of the present invention can be formulated into pharmaceutical compositions and raw material pharmaceutical compositions suitable for preparing dosage forms using techniques well known to those skilled in the art. In addition to those mentioned herein, suitable pharmaceutically acceptable carriers known in the art are, for example, seen in Remington, The Science and Practice of Pharmacy, 20th edition, 2000, Lippincott Williams & Wilkins, (Editors: Gennaro et al.).

[0283] While the salts of the present invention may be administered as raw materials or pure chemicals for prevention or treatment in alternative uses, it is preferred to present the salt or active ingredient as a pharmaceutical preparation or composition further comprising a pharmaceutically acceptable carrier.

[0284] Drug preparations include being suitable for oral, rectal, nasal, local (including buccal and sublingual), vaginal or parenteral (including intramuscular, subcutaneous and intravenous) use, or with the preparation of the form suitable for by suction, insufflation or by transdermal patch application.Transdermal patch is by making medicine for absorption in an effective manner, minimizes drug degradation simultaneously, distributes medicine with controlled rate.Usually, transdermal patch includes impermeable backing layer (backing layer), single pressure-sensitive adhesive and the removable protective layer with release liner.Those of ordinary skill in the art will understand and recognize the appropriate technology of the effective transdermal patch of expectation based on the needs of technicians.

[0285] Therefore, the salt of the present invention can be made into the form of pharmaceutical preparations and unit dosage forms thereof together with conventional adjuvants, carriers or diluents, and in such a form, it can be used as a solid such as a tablet or a filled capsule, or a liquid such as a solution, a suspension, an emulsion, an elixir, a gel or a capsule filled with the liquid, all for oral administration, in the form of a suppository for rectal administration; or in the form of a sterile injection solution for parenteral (including subcutaneous) use. Such pharmaceutical compositions and unit dosage forms thereof can contain conventional ingredients in conventional proportions, with or without additional active compounds or ingredients, and such unit dosage forms can contain any suitable effective amount of active ingredients commensurate with the expected daily dosage range to be used.

[0286] For oral administration, the pharmaceutical composition can be in the form of, for example, tablets, capsules, suspensions or liquids. The pharmaceutical composition is preferably prepared in the form of a dosage unit containing a specific amount of the active ingredient. Examples of such dosage units are capsules, tablets, powders, granules or suspensions with conventional additives such as lactose, mannitol, corn starch or potato starch; with binders such as crystalline cellulose, cellulose derivatives, gum arabic, corn starch or gelatin; with disintegrants such as corn starch, potato starch or sodium carboxymethylcellulose; and with lubricants such as talc or magnesium stearate. The active ingredient can also be administered as a composition by injection, wherein, for example, saline, dextrose or water can be used as a suitable pharmaceutically acceptable carrier.

[0287] The compounds of the present invention or their salts, solvates, hydrates or physiologically functional derivatives can be used as active ingredients in pharmaceutical compositions, in particular as S1P1 receptor modulators. The term "active ingredient" is defined in the context of "pharmaceutical composition" and refers to the component of the pharmaceutical composition that provides the main pharmacological effect, rather than "inactive ingredients" that are generally considered to provide no pharmaceutical benefit.

[0288] The dosage when using the salt of the present invention can vary within a wide range, and according to convention and known to doctors, the dosage will be adjusted for the individual condition in each individual case. This depends, for example, on the nature and severity of the disease to be treated, on the patient's condition, on the salt used, or on whether an acute or chronic disease condition is treated or prevented, or on whether to apply another active compound in addition to the salt of the present invention. Representative dosages of the present invention include, but are not limited to, about 0.001 mg to about 5000 mg, about 0.001 mg to about 2500 mg, about 0.001 mg to about 1000 mg, about 0.001 mg to about 500 mg, about 0.001 mg to about 250 mg, about 0.001 mg to 100 mg, about 0.001 mg to about 50 mg, and about 0.001 mg to about 25 mg. Multiple doses can be applied during the day, particularly when it is considered that a relatively large amount is needed, such as 2, 3 or 4 doses. It may be necessary to deviate upward or downward from the dosage described herein as appropriate according to the individual and patient's physician or caregiver.

[0289] The amount of the active ingredient or active salt or its derivative required for treatment will not only vary with the selected specific salt, but also with the route of administration, the nature of the disease being treated and the age and condition of the patient, and will ultimately be determined by the assistant physician or clinician. Generally, those skilled in the art understand how to extrapolate the in vivo data obtained in a model system (usually an animal model) to another model, such as humans. In some cases, these extrapolations can be based only on the weight of the animal model compared to another model (such as mammals, preferably humans), however, more commonly, these extrapolations are not simply based on weight, but include various factors. Representative factors include the type, age, weight, sex, diet and medical conditions of the patient, the severity of the disease, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicological profile of the specific salt used, whether a drug delivery system is used, whether an acute or chronic disease condition is being treated or prevented, or whether to apply another active compound in addition to the salt of the present invention and as part of a pharmaceutical composition. The dosage regimen for treating disease conditions with the salt and / or composition of the present invention is selected according to various factors as described above. Thus, the actual dosage regimen employed may vary widely and therefore may deviate from the preferred dosage regimen, and one skilled in the art will recognize that doses and dosage regimens outside of these typical ranges can be tested and, where appropriate, used in the methods of the present invention.

[0290] The desired dosage can be conveniently provided as a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-doses themselves can be further divided, for example, into a number of discrete loosely spaced administrations. The daily dose can be divided into a number of, for example, 2, 3 or 4 partial administrations, particularly when it is considered appropriate to administer a relatively large amount. If appropriate, depending on individual behavior, it may be necessary to deviate upward or downward from the indicated daily dose.

[0291] The salts of the present invention can be administered in various oral and parenteral dosage forms. It is obvious to those skilled in the art that the following dosage forms may contain the salts of the present invention or solvates or hydrates of the salts of the present invention as active ingredients.

[0292] For preparing pharmaceutical compositions from the compounds of the present invention, the choice of suitable pharmaceutically acceptable carriers can be solid, liquid, or a mixture of the two. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances that can also act as a diluent, flavoring agent, solubilizer, lubricant, suspending agent, binder, preservative, tablet disintegrating agent, or encapsulating material.

[0293] In powders, the carrier is a finely divided solid, which is in admixture with the finely divided active component.

[0294] In tablets, the active ingredient is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.

[0295] Powders and tablets may contain varying percentages of active salt. A representative amount in a powder or tablet may contain from 0.5% to about 90% of the active salt; however, the skilled artisan will know when amounts outside this range are necessary. Suitable carriers for powders and tablets are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, low melting waxes, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active salt with encapsulating material as a carrier, which provides a capsule in which the active ingredient (with or without a carrier) is surrounded by a carrier, which is thus combined with the active ingredient. Similarly, cachets and lozenges are also included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.

[0296] For preparing suppositories, a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted and the active ingredient is dispersed uniformly therein by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

[0297] Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

[0298] Liquid form preparations include solutions, suspensions and emulsions, for example, water or water-propylene glycol solutions. For example, parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solutions. Injection preparations, such as sterile injection aqueous or oily suspensions, can be prepared using suitable dispersants or wetting agents and suspending agents according to known techniques. Sterile injection preparations can also be sterile injection solutions or suspensions in non-toxic parenteral acceptable diluents or solvents, for example, as solutions in 1,3-butanediol. Acceptable vehicles and solvents that can be used are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils are generally used as solvents or suspension media. For this purpose, any mild fixed oil can be used, including synthetic monoglycerides or diglycerides. In addition, fatty acids such as oleic acid can be used to prepare injections.

[0299] Therefore, the compound according to the present invention can be formulated for parenteral administration (e.g., by injection, such as push injection or continuous infusion) and can be provided in unit dose form in ampoules, pre-filled syringes (pre-filledsyringes), small volume infusions or in multiple dose containers with added preservatives. The pharmaceutical composition can take the form of an emulsion such as a suspension, a solution or in an oil or water vehicle and can contain a formulation agent such as a suspending agent, a stabilizer and / or a dispersant. Alternatively, the active ingredient can be in the form of a powder obtained by aseptic separation of sterile solids or by freeze drying from a solution, for preparation with suitable vehicles such as sterile, pyrogen-free water before use.

[0300] Aqueous preparations suitable for oral use can be prepared by dissolving or suspending the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents, as desired.

[0301] Aqueous suspensions suitable for oral use can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well-known suspending agents.

[0302] Also included are solid form preparations that are intended to be converted into liquid form preparations for oral administration shortly before use. Such liquid forms include solutions, suspensions, and emulsions. These preparations may also contain colorants, flavorings, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, etc. in addition to the active ingredient.

[0303] For topical administration to the epidermis, the salts according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch.

[0304] For example, ointments and creams can be formulated with an aqueous or oily base with the addition of suitable thickeners and / or gelling agents. Lotions can be formulated with an aqueous or oily base and will generally also contain one or more emulsifiers, stabilizers, dispersants, suspending agents, thickeners or colorants.

[0305] Formulations suitable for topical administration in the mouth include lozenges comprising the active agent in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

[0306] The solution or suspension is applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or sprayer. The preparation can be provided in single or multiple doses. In the latter case of a dropper or pipette, this can be achieved by the patient administering a suitable, predetermined volume of the solution or suspension. In the case of a spray, this can be achieved by means of, for example, a metered atomizing spray pump.

[0307] Administration to the respiratory tract can also be achieved by the method of aerosol formulation, wherein the active ingredient is provided in a pressurized package with a suitable propellant. If the salt of the present invention or the pharmaceutical composition comprising them is used as an aerosol (e.g., as a nasal aerosol) or by inhalation, this can be implemented, for example, using a sprayer, atomizer, a pump atomizer, an inhalation device, a metered dose inhaler or a dry powder inhaler. The pharmaceutical form for administering the salt of the present invention as an aerosol can be prepared by methods well known to those skilled in the art. For their preparation, for example, a solution or dispersion of the salt of the present invention in water, a water / alcohol mixture or a suitable saline solution can be adopted, which uses conventional additives such as benzyl alcohol or other suitable preservatives, absorption promoters for improving bioavailability, solubilizers, dispersants, etc., and conventional propellants such as carbon dioxide, chlorofluorocarbons (CFCs), such as dichlorodifluoromethane, trichlorofluoromethane or dichlorotetrafluoroethane, etc., if appropriate. Aerosols can also conveniently contain surfactants such as lecithin. The dosage of the drug can be controlled by providing a metered valve.

[0308] In preparations intended for administration to the respiratory tract, including intranasal preparations, the salts generally have a small particle size, for example, of the order of 10 microns or less. Such a particle size can be obtained by methods known in the art, for example, by micronization. When desired, a preparation suitable for producing a sustained release of the active ingredient can be used.

[0309] Alternatively, the active ingredient may be provided in the form of a dry powder, for example, a powder mixture of a salt in a suitable powder base such as lactose, starch, a starch derivative (such as hydroxypropylmethylcellulose) and polyvinylpyrrolidone (PVP). Conveniently, the powder carrier will form a gel in the nasal cavity. The powder composition may be provided in unit dose form, for example in capsules or cartridges (e.g., of gelatin), or in blister packs from which the powder can be administered by means of an inhaler.

[0310] The pharmaceutical formulation is preferably in unit dosage form. In such form, the formulation is subdivided into unit doses containing appropriate quantities of the active ingredient. The unit dosage form can be a packaged formulation, the package containing discrete quantities of the formulation, such as packaged tablets, capsules, and powders in vials or ampoules. The unit dosage form can also be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

[0311] Tablets or capsules for oral administration and liquids for intravenous administration are preferred compositions.

[0312] The present invention relates to a pharmaceutical composition comprising each combination of one or more salts or crystalline forms selected from the following groups:

[0313] (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), diethanolamine salt;

[0314] (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) diethylamine salt

[0315] One aspect of the present invention relates to a pharmaceutical composition comprising (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) diethanolamine salt and a pharmaceutically acceptable carrier.

[0316] One aspect of the present invention relates to a pharmaceutical composition comprising a crystalline form of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) diethanolamine salt and a pharmaceutically acceptable carrier.

[0317] One aspect of the present invention relates to a pharmaceutical composition comprising (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) diethylamine salt and a pharmaceutically acceptable carrier.

[0318] One aspect of the present invention relates to a pharmaceutical composition comprising a crystalline form of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) diethylamine salt and a pharmaceutically acceptable carrier.

[0319] Acid addition salts can be obtained as direct products of compound synthesis. In alternative schemes, the free base can be dissolved in a suitable solvent containing an appropriate acid and the salt can be isolated by evaporating the solvent or other means of separating the salt from the solvent. The compounds of the present invention can form solvates with standard low molecular weight solvents using methods known to those skilled in the art.

[0320] The compounds of the present invention can be converted into "prodrugs". The term "prodrug" refers to a compound that has been modified with specific chemical groups known in the art, and when administered to an individual, these groups undergo biotransformation to produce the parent compound. Therefore, a prodrug can be considered a compound of the present invention that contains one or more dedicated non-toxic protective groups that are used to change or eliminate the properties of the compound in a temporary manner. In a general aspect, the "prodrug" method is used to promote oral absorption. A comprehensive discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems Vol. 14 of the ACSSymposium Series; and in Bioreversible Carriers in Drug Design, Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference in their entirety.

[0321] Embodiments of the present invention include methods of preparing a pharmaceutical composition for "combination therapy" comprising mixing at least one compound according to any of the compound embodiments disclosed herein with at least one known agent as described herein and a pharmaceutically acceptable carrier.

[0322] It should be noted that when S1P1 receptor modulators are used as active ingredients in pharmaceutical compositions, these are not intended for use only in humans, but also in other non-human mammals. Indeed, recent advances in the field of animal health care indicate that active agents such as S1P1 receptor modulators are contemplated for use in treating S1P-related diseases or disorders in companion animals (e.g., cats, dogs, etc.) and livestock animals (e.g., cattle, chickens, fish, etc.). One of ordinary skill in the art would readily be considered to understand the utility of such compounds in such settings. Example

[0323] The following examples are provided to further define the present invention, but the present invention is not limited to the details of these examples. The above and following compounds and salts thereof described herein are named according to CS ChemDraw Ultra Version 7.0.1, AutoNom Version 2.2 or CS ChemDraw Ultra Version 9.0.7. In some cases, common names are used, and it should be understood that these common names will be recognized by those skilled in the art.

[0324] Powder X-ray diffraction (PXRD) analysis was performed on a PANalytical X'pert pro with a PIXcel detector (128 channels), scanning the sample between 3° and 35° 2θ. The material was gently ground to release any lumps and loaded onto a porous plate with a Mylar polymer film to support the sample. The porous plate was then placed in the diffractometer and the CuK radiation ( α 1 :α 2 Ratio = 0.5) was analyzed using a 40 kV / 40 mA generator setting running in transmission mode (step size 0.0130° 2θ, step time 18.87 s). Data were visualized and images were generated using the HighScore Plus 4.8 desktop application (PANalytical, 2017).

[0325] About 1-5 mg of material was weighed into an aluminum DSC pan and sealed non-hermetically with an aluminum lid. The sample pan was then loaded into a TA Instruments Discovery DSC 2500 differential scanning calorimeter equipped with an RC90 cooler. The samples and reference were heated to 220°C at a scan rate of 10°C / min and the resulting heat flow response was monitored. The samples were recooled to 20°C and then reheated to 220°C at 10°C / min. Nitrogen was then added at 50 cm 3 A flow rate of 1.25 / min was used as the purge gas.

[0326] About 5-10 mg of material was added to a pre-peeled open aluminum pan and loaded into a TA Instruments Discovery SDT 650 Auto-Simultaneous DSC and kept at room temperature. The sample was then heated from 30°C to 400°C at a rate of 10°C / min, during which the change in sample weight and heat flow response (DSC) were recorded. Nitrogen was purged at 200 cm 3 / min flow rate is used as sample purge gas

[0327] Example 1: Preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) diethanolamine salt (Compound 1 diethanolamine salt).

[0328] - (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (140 mg) was suspended in acetonitrile (400 μL) in a 20 mL vial.

[0329] - Diethanolamine (1.05 eq.) was added followed by water (10 μL).

[0330] - Seed crystals (1-2 mg) were added followed by a stir bar and the vial was sealed with parafilm.

[0331] • Solids settled in about 5 minutes and were isolated by centrifugation.

[0332] The isolated solid was dried under vacuum at ambient temperature for 24 hours to yield an orange solid (165 mg, 96%).

[0333] The powder X-ray diffraction pattern of the title salt is shown at Figure 1 The thermal analysis (DSC and TGA) of the title salt were shown in Figure 2 and Figure 3 middle.

[0334] Preparation of seed crystals of diethanolamine salt of compound 1

[0335] - (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (140 mg) was suspended in acetonitrile (400 μL) in a 20 mL vial.

[0336] - Diethanolamine (1.05 eq.) was added followed by water (10 μL).

[0337] - A stir bar was added to the resulting mixture and the vial was sealed with parafilm.

[0338] - Seal the vial and cycle the temperature between 5°C and 40°C at a heating / cooling rate of 0.1°C / min and hold at each temperature for 1 hour while stirring for 24 hours.

[0339] - Cool the mixture to 5°C.

[0340] • The solid was isolated by centrifugation and then dried under vacuum at ambient temperature for 24 hours.

[0341] Example 2: Preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) diethylamine salt (Compound 1 diethylamine salt).

[0342] • Weigh (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (250 mg) into a 20 mL vial.

[0343] • The sample was suspended in acetonitrile (1 mL).

[0344] · Add 1.05 equivalents of diethylamine.

[0345] - Add water (20 μL) to the diethylamine sample.

[0346] - Seal the vial and cycle the temperature between 5°C and 40°C at a heating / cooling rate of 0.1°C / min and hold at each temperature for 1 hour while stirring for 24 hours.

[0347] • The solid was isolated by centrifugation and dried under vacuum at ambient temperature for 24 hours.

[0348] The solid was further characterized by PXRD and TG / DSC.

[0349] The powder X-ray diffraction pattern of the title salt is shown at Figure 4 The thermal analysis (DSC and TGA) of the title salt were shown in Figure 5 and Figure 6 middle.

[0350] Those skilled in the art will appreciate that various modifications, additions, substitutions and changes may be made to the illustrative embodiments described herein without departing from the spirit of the invention and such modifications, additions, substitutions and changes are considered to be within the scope of the invention.

Claims

1. A crystalline salt selected from: (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid diethanolamine salt; (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid diethylamine salt; and pharmaceutically acceptable solvates and hydrates thereof.

2. The crystalline salt according to claim 1, which is (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid diethanolamine salt.

3. The diethanolamine salt according to any one of claims 1 to 2, which has an X-ray powder diffraction pattern comprising peaks expressed in 2θ at 8.5°±0.2° and 11.6°±0.2°.

4. The diethanolamine salt according to any one of claims 1 to 2, which has an X-ray powder diffraction pattern comprising peaks expressed in 2θ at 8.5°±0.2°, 11.6°±0.2°, 11.8°±0.2° and 12.1°±0.2°.

5. The diethanolamine salt according to any one of claims 1 to 2, which has an X-ray powder diffraction pattern comprising peaks expressed in 2θ at 8.5°±0.2°, 11.6°±0.2°, 11.8°±0.2°, 12.1°±0.2°, 13.1°±0.2°, 14.5°±0.2° and 18.7°±0.2°.

6. The diethanolamine salt according to any one of claims 1 to 2, which has an X-ray powder diffraction pattern comprising peaks expressed in 2θ at 8.5°±0.2°, 11.6°±0.2°, 11.8°±0.2°, 12.1°±0.2°, 13.1°±0.2°, 14.5°±0.2°, 18.7°±0.2°, 20.1°±0.2°, 20.4°±0.2° and 22.0°±0.2°.

7. The diethanolamine salt according to any one of claims 1 to 2, which has an X-ray powder diffraction pattern comprising peaks expressed in terms of 2θ at 8.5°±0.2°, 11.6°±0.2°, 11.8°±0.2°, 12.1°±0.2°, 13.1°±0.2°, 14.5°±0.2°, 18.7°±0.2°, 20.1°±0.2°, 20.4°±0.2°, 22.0°±0.2°, 22.2°±0.2°, 23.1°±0.2° and 24.5°±0.2°.

8. The diethanolamine salt according to any one of claims 1 to 2, having an X-ray powder diffraction pattern substantially as shown in Figure 1.

9. The diethanolamine salt according to any one of claims 1 to 8, wherein the salt has a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature between about 120.5°C and about 130.4°C.

10. The diethanolamine salt according to any one of claims 1 to 8, wherein the salt has a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature between about 120.5°C and about 129.4°C.

11. The diethanolamine salt according to any one of claims 1 to 8, wherein the salt has a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature between about 121.5°C and about 129.4°C.

12. The diethanolamine salt according to any one of claims 1 to 8, wherein the salt has a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature between about 121.5°C and about 128.4°C.

13. The diethanolamine salt according to any one of claims 1 to 8, wherein the salt has a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature between about 122.5°C and about 128.4°C.

14. The diethanolamine salt according to any one of claims 1 to 8, wherein the salt has a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature at about 123.5°C.

15. The diethanolamine salt according to any one of claims 1 to 8, wherein the salt has a differential scanning calorimetry thermogram substantially as shown in Figure 2.

16. The diethanolamine salt of any one of claims 1-15, wherein the salt has a thermogravimetric analysis spectrum showing a weight loss of about 14.8% below about 130°C.

17. The diethanolamine salt of any one of claims 1-15, wherein the salt has a thermogravimetric analysis spectrum showing a weight loss of about 13.8% below about 130°C.

18. The diethanolamine salt of any one of claims 1-15, wherein the salt has a thermogravimetric analysis spectrum showing a weight loss of about 12.8% or less below about 130°C.

19. The diethanolamine salt according to any one of claims 1 to 15, wherein the salt has a thermogravimetric analysis pattern substantially as shown in Figure 3.

20. The diethanolamine salt according to any one of claims 1-2, wherein the salt has: a) an X-ray powder diffraction pattern comprising peaks expressed in 2θ at 8.5°±0.2° and 11.6°±0.2°; b) a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature between about 120.5°C and about 130.4°C.

21. The diethanolamine salt according to any one of claims 1-2, wherein the salt has: a) an X-ray powder diffraction pattern comprising peaks, expressed in 2θ, at 8.5°±0.2°, 11.6°±0.2°, 11.8°±0.2° and 12.1°±0.2°; b) a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature between about 120.5°C and about 129.4°C.

22. The diethanolamine salt according to any one of claims 1-2, wherein the salt has: a) an X-ray powder diffraction pattern comprising peaks, expressed in 2θ, at 8.5°±0.2°, 11.6°±0.2°, 11.8°±0.2°, 12.1°±0.2°, 13.1°±0.2°, 14.5°±0.2° and 18.7°±0.2°; b) a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature between about 121.5°C and about 129.4°C.

23. The diethanolamine salt according to any one of claims 1-2, wherein the salt has: a) an X-ray powder diffraction pattern comprising peaks, expressed in 2θ, at 8.5°±0.2°, 11.6°±0.2°, 11.8°±0.2°, 12.1°±0.2°, 13.1°±0.2°, 14.5°±0.2°, 18.7°±0.2°, 20.1°±0.2°, 20.4°±0.2°, and 22.0°±0.2°; b) a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature between about 121.5°C and about 128.4°C; and / or c) Thermogravimetric analysis spectrum showing a weight loss of about 14.8% below about 130°C.

24. The diethanolamine salt according to any one of claims 1-2, wherein the salt has: a) an X-ray powder diffraction pattern comprising peaks, expressed in 2θ, at 8.5°±0.2°, 11.6°±0.2°, 11.8°±0.2°, 12.1°±0.2°, 13.1°±0.2°, 14.5°±0.2°, 18.7°±0.2°, 20.1°±0.2°, 20.4°±0.2°, 22.0°±0.2°, 22.2°±0.2°, 23.1°±0.2°, and 24.5°±0.2°; b) a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature between about 122.5°C and about 128.4°C; and / or c) Thermogravimetric analysis spectrum showing a weight loss of about 13.8% below about 130°C.

25. The diethanolamine salt according to any one of claims 1-2, wherein the salt has: a) an X-ray powder diffraction pattern comprising peaks, expressed in 2θ, at 8.5°±0.2°, 11.6°±0.2°, 11.8°±0.2°, 12.1°±0.2°, 13.1°±0.2°, 14.5°±0.2°, 18.7°±0.2°, 20.1°±0.2°, 20.4°±0.2°, 22.0°±0.2°, 22.2°±0.2°, 23.1°±0.2°, and 24.5°±0.2°; b) a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature at about 123.5°C; and / or c) Thermogravimetric analysis spectrum showing a weight loss of about 12.8% below about 130°C.

26. The diethanolamine salt according to any one of claims 1-2, wherein the salt has: a) an X-ray powder diffraction pattern substantially as shown in Figure 1; b) a differential scanning calorimetry thermogram substantially as shown in Figure 2; and / or c) a thermogravimetric analysis pattern substantially as shown in Figure 3.

27. The crystalline salt according to claim 1, which is (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid diethylamine salt.

28. The diethylamine salt according to any one of claims 1 or 27, which has an X-ray powder diffraction pattern comprising peaks expressed in 2θ at 7.9°±0.2° and 8.5°±0.2°.

29. The diethylamine salt according to any one of claims 1 or 27, which has an X-ray powder diffraction pattern comprising peaks expressed in 2θ at 7.9°±0.2°, 8.5°±0.2°, 12.8°±0.2° and 15.6°±0.2°.

30. The diethylamine salt according to any one of claims 1 or 27, which has an X-ray powder diffraction pattern comprising peaks expressed in 2θ at 7.9°±0.2°, 8.5°±0.2°, 12.8°±0.2°, 15.6°±0.2°, 15.9°±0.2° and 17.0°±0.2°.

31. The diethylamine salt according to any one of claims 1 or 27, which has an X-ray powder diffraction pattern comprising peaks expressed in 2θ at 7.9°±0.2°, 8.5°±0.2°, 12.8°±0.2°, 15.6°±0.2°, 15.9°±0.2°, 17.0°±0.2°, 19.0°±0.2°, 19.3°±0.2°, and 19.8°±0.2°.

32. The diethylamine salt according to any one of claims 1 or 27, which has an X-ray powder diffraction pattern comprising peaks expressed in terms of 2θ at 7.9°±0.2°, 8.5°±0.2°, 12.8°±0.2°, 15.6°±0.2°, 15.9°±0.2°, 17.0°±0.2°, 19.0°±0.2°, 19.3°±0.2°, 19.8°±0.2°, 20.3°±0.2°, 22.5°±0.2°, 23.1°±0.2°, and 26.8°±0.2°.

33. The diethylamine salt according to any one of claims 1 or 27, having an X-ray powder diffraction pattern substantially as shown in Figure 4.

34. The diethylamine salt according to any one of claims 1 and 27-33, wherein the salt has a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature between about 104.6°C and about 119.4°C.

35. The diethylamine salt according to any one of claims 1 and 27-33, wherein the salt has a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature between about 104.6°C and about 118.4°C.

36. The diethylamine salt according to any one of claims 1 and 27-33, wherein the salt has a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature between about 105.6°C and about 118.4°C.

37. The diethylamine salt according to any one of claims 1 and 27-33, wherein the salt has a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature between about 105.6°C and about 117.4°C.

38. The diethylamine salt according to any one of claims 1 and 27-33, wherein the salt has a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature between about 106.6°C and about 116.4°C.

39. The diethylamine salt according to any one of claims 1 and 27-33, wherein the salt has a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature at about 107.6°C.

40. The diethylamine salt according to any one of claims 1 and 27-33, wherein the salt has a differential scanning calorimetry thermogram substantially as shown in Figure 5.

41. The diethylamine salt according to any one of claims 27-40, wherein the salt has a thermogravimetric analysis spectrum showing a weight loss of about 4.9% below about 110°C.

42. The diethylamine salt according to any one of claims 27-40, wherein the salt has a thermogravimetric analysis spectrum showing a weight loss of about 3.9% below about 110°C.

43. The diethylamine salt according to any one of claims 27-40, wherein the salt has a thermogravimetric analysis spectrum showing a weight loss of about 2.9% or less below about 110°C.

44. The diethylamine salt according to any one of claims 27 to 40, wherein the salt has a thermogravimetric analysis pattern substantially as shown in Figure 6.

45. The diethylamine salt according to any one of claims 1 and 27, wherein the salt has: a) an X-ray powder diffraction pattern comprising peaks expressed in 2θ at 7.9°±0.2° and 8.5°±0.2°; b) a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature between about 104.6°C and about 119.4°C.

46. ​​The diethylamine salt according to any one of claims 1 and 27, wherein the salt has: a) an X-ray powder diffraction pattern comprising peaks, expressed in 2θ, at 7.9°±0.2°, 8.5°±0.2°, 12.8°±0.2° and 15.6°±0.2°; b) a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature between about 104.6°C and about 118.4°C.

47. The diethylamine salt according to any one of claims 1 and 27, wherein the salt has: a) an X-ray powder diffraction pattern comprising peaks, expressed in 2θ, at 7.9°±0.2°, 8.5°±0.2°, 12.8°±0.2°, 15.6°±0.2°, 15.9°±0.2° and 17.0°±0.2°; b) a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature between about 105.6°C and about 118.4°C.

48. The diethylamine salt according to any one of claims 1 and 27, wherein the salt has: a) an X-ray powder diffraction pattern comprising peaks, expressed in 2θ, at 7.9°±0.2°, 8.5°±0.2°, 12.8°±0.2°, 15.6°±0.2°, 15.9°±0.2°, 17.0°±0.2°, 19.0°±0.2°, 19.3°±0.2°, and 19.8°±0.2°; b) a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature between about 105.6°C and about 117.4°C; and / or c) Thermogravimetric analysis spectrum showing a weight loss of about 4.9% below about 110°C.

49. The diethylamine salt according to any one of claims 1 and 27, wherein the salt has: a) an X-ray powder diffraction pattern comprising peaks, expressed in 2θ, at 7.9°±0.2°, 8.5°±0.2°, 12.8°±0.2°, 15.6°±0.2°, 15.9°±0.2°, 17.0°±0.2°, 19.0°±0.2°, 19.3°±0.2°, 19.8°±0.2°, 20.3°±0.2°, 22.5°±0.2°, 23.1°±0.2°, and 26.8°±0.2°; b) a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature between about 106.6°C and about 116.4°C; and / or c) Thermogravimetric analysis spectrum showing a weight loss of about 3.9% below about 110°C.

50. The diethylamine salt according to any one of claims 1 and 27, wherein the salt has: a) an X-ray powder diffraction pattern comprising peaks, expressed in 2θ, at 7.9°±0.2°, 8.5°±0.2°, 12.8°±0.2°, 15.6°±0.2°, 15.9°±0.2°, 17.0°±0.2°, 19.0°±0.2°, 19.3°±0.2°, 19.8°±0.2°, 20.3°±0.2°, 22.5°±0.2°, 23.1°±0.2°, and 26.8°±0.2°; b) a differential scanning calorimetry thermogram comprising an endotherm with an extrapolated onset temperature at about 107.6°C; and / or c) Thermogravimetric analysis spectrum showing a weight loss of about 2.9% below about 110°C.

51. The diethylamine salt according to any one of claims 1 and 27, wherein the salt has: a) an X-ray powder diffraction pattern substantially as shown in Figure 4; b) a differential scanning calorimetry thermogram substantially as shown in Figure 5; and / or c) a thermogravimetric analysis pattern substantially as shown in Figure 6.

52. A pharmaceutical composition comprising a crystalline salt according to any one of claims 1 to 51 and a pharmaceutically acceptable carrier.

53. A process for preparing a pharmaceutical composition comprising mixing a crystalline salt according to any one of claims 1 to 51 and a pharmaceutically acceptable carrier.

54. A method for treating an S1P1 receptor-associated disorder in an individual, comprising administering to the individual in need thereof a therapeutically effective amount of a crystalline salt according to claim 1, 2 or 27 or a pharmaceutical composition according to claim 52.

55. Use of a crystalline salt according to claim 1, 2 or 27 for the preparation of a medicament for the treatment of an S1P1 receptor-related disorder.

56. A crystalline salt according to claim 1, 2 or 27, or a pharmaceutical composition according to claim 52, for use in a method of treatment of the human or animal body by therapy.

57. A crystalline salt according to claim 1, 2 or 27, or a pharmaceutical composition according to claim 52, for use in a method of treating an S1P1 receptor-associated disorder.

58. The method according to claim 54, the use according to claim 55, the crystalline salt according to claims 56, 57, or the pharmaceutical composition according to claim 52, wherein the S1P1 receptor-associated disorder is selected from the group consisting of psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, myocardial ischemia-reperfusion injury, hypertensive nephropathy, glomerulosclerosis, gastritis, polymyositis, thyroiditis, vitiligo, hepatitis and biliary cirrhosis.

59. A method for preparing a crystalline salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, comprising the following steps: a) mixing (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid in an organic solvent to produce a suspension; b) adding an amine to the suspension followed by water; and c) isolating the crystalline salt.

60. The method according to claim 59, wherein the organic solvent is selected from the group consisting of tetrahydrofuran (THF), 2-propanol, acetonitrile, ethyl acetate, ethanol, tert-butyl methyl ether (TBME), methyl isobutyl ketone (MIBK), water and dimethyl sulfoxide (DMSO), and combinations thereof.

61. The method according to claim 60, wherein the organic solvent is acetonitrile.

62. The method according to any one of claims 59 to 61, wherein the amine is selected from the group consisting of diethylamine, dimethylethanolamine, ethanolamine, diethanolamine, morpholine, tromethamine, N-methyl-D-glucamine, diethylethanolamine and pyrrolidine.

63. The process according to claim 62, wherein the amine is diethylamine.

64. The method according to claim 62, wherein the amine is diethanolamine.

65. The method according to any one of claims 59 to 64, wherein the separating step further comprises the following steps: a) adding seed crystals of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, followed by stirring; and b) cycling the temperature between 5°C and 40°C at a heating / cooling rate of 0.1°C / min and holding at each temperature for 1 hour while stirring for 24 hours; and c) The precipitated solid was collected by filtration.